Experimental approaches to study cerebral amyloidosis in a transgenic mouse model of Alzheimer's disease by Meyer-Lühmann, Melanie
Experimental approaches to study cerebral
amyloidosis in a transgenic mouse model of
Alzheimer’s disease
Inauguraldissertation
 zur
Erlangung der Würde eines Doktors der Philosophie
vorgelegt der
 Philosophisch-Naturwissenschaftlichen Fakultät
 der Universität Basel
von
Melanie Meyer-Lühmann
aus Deutschland
Basel, 2004
2Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät
auf Antrag von
Prof. Dr. Heinrich Reichert und Prof. Dr. Mathias Jucker
Basel, den 10. Februar 2004
Prof. Dr. Marcel Tanner
Dekan
3 Acknowledgements
First I would like to express special thanks to my supervisor Prof. Mathias Jucker for
giving me the opportunity to carry out my PhD thesis and for supporting me throughout
my doctoral work. In particular, I want to thank him for his enthusiasm towards my
results and for supporting my participation at scientific international meetings.
Additionally, I would also like to thank Prof. Heinrich Reichert and Prof. Konrad
Beyreuther for their academical support and participation in this dissertation.
I am grateful to Prof. Michael Mihatsch for hosting my work at the Institute of
Pathology. I would also like to acknowledge Prof. Alphonse Probst and Prof. Markus
Tolnay for their advice as neuropathologists.
I am grateful to Martina Stalder, David Winkler, Luca Bondolfi, Sonia Boncristiano,
Florian Ermini, Stephan Käser, Tristan Bolmont and Florence Clavaguera who were
always a great help and a good companion during the daily lab life. I am especially
indebted to Esther Kohler and Anne Stalder for their psychological support and Martin
Herzig for his endless patience and help with my computer and other kinds of problems
and for his friendship. Special thanks goes to Michelle Pfeifer, Janaky Coomaraswamy
and Michelle Moore for proofreading the manuscript.
I would like to adress my special thank to the members of the photo group Thomas
Schürch, Hans-Ruedi Zysset and Jan Schwegler for their help in preparing presentations
and manuscripts.
I am grateful to Dr. Matthias Staufenbiel at Novartis in Basel and the members of his
group for the general support of my studies and for scientific discussions.
I am indebted to Prof. Hans-Christoph Spatz at the University of Freiburg and Prof.
John Wayne Aldridge at the University of Michigan at Ann Arbor who guided my first
steps in science during my Diploma thesis and made my affinity for neuroscience grow.
I am grateful to my friends for bearing with me, as I worked my way to the end of this
thesis.
Thanks are also due to my parents and Winfried Elis for encouraging me in this
endeavor. Without their support of course, none of this would have been possible.
This work is dedicated to the memory of my grandmother Martha Huck.
4Table of contents
Summary 6
1. Introduction 9
1.1 Protein misfolding in age-related neurodegenerative diseases 9
1.2 Alzheimer’s disease 11
1.2.1 Neuropathological hallmarks 12
1.2.2 Genetics of Alzheimer’s disease 16
1.2.3 APP processing and Ab 17
1.2.4 Mouse models of Alzheimer’s disease 21
1.2.5 Therapeutic approaches 22
1.3 Studying cerebral amyloidosis in vivo 26
1.3.1 Intracerebral grafting 26
1.3.2 Seeding mechanism 28
1.3.3 Magnetic resonance imaging 29
1.4 References 31
2. Extracellular amyloid formation and associated pathology
in neural grafts 50
2.1 Abstract 51
2.2 Introduction 52
2.3 Results 53
2.4 Discussion 59
2.5 Materials and Methods 62
2.6 References 67
2.7 Figure Captions 71
53. Seeding of cerebral amyloidosis in APP23 transgenic mice 84
3.1 Abstract 85
3.2 Introduction 86
3.3 Results 87
3.4 Discussion 90
3.5 Materials and Methods 92
3.6 References 96
3.7 Figure Captions 100
4. Restricted cortical apparent diffusion coefficient
in APP23 transgenic mice 111
4.1 Abstract 112
4.2 Introduction 113
4.3 Results 114
4.4 Discussion 116
4.5 Materials and Methods 118
4.6 References 122
4.7 Figure Captions 125
5. Conclusion 134
6. Abbreviations 136
7. Curriculum vitae 137
8. Bibliography 138
6Summary
Misfolding, aggregation and the accumulation of proteins in the brain are common
characteristics of diverse age-related neurodegenerative diseases. Each of these
neurodegenerative diseases is associated with abnormalities in the folding of a different
protein leading to protein aggregation and finally to neuronal death. Alzheimer’s
disease (AD) is one of these protein conformational diseases characterized by two major
neuropathological features: extracellular accumulation of amyloid-b (Ab) peptide in the
form of plaques and intracellular tangles consisting of hyperphosphorylated tau protein.
Although the majority of AD cases are sporadic, three genes have been described whose
mutations cause early-onset familial AD (FAD). The identification of mutations in these
genes has provided new opportunities to explore pathogenic mechanisms using
transgenic approaches. Based on the finding that mutations in these genes all lead to
elevated levels of Ab, new anti-amyloid therapies have been developed to either lower
the production of Ab or to clear the amyloid peptides.
In the past few years, several groups have generated transgenic mouse models of
cerebral amyloidosis that exhibit age related Ab deposition similar to AD patients
through expression of mutated human amyloid precursor protein (APP). The studies
presented herein were done using such a transgenic mouse model, the APP23 mouse,
that overexpresses human APP with the Swedish mutation under the control of a neuron
specific Thy-1 promotor. APP23 transgenic mice develop cerebral amyloidosis in an
age- and region-dependent manner. Plaque formation starts early at 6 months of age and
is associated with the typical AD-like pathology including cerebral amyloid angiopathy,
neuron loss, glial activation and cognitive impairment.
The purpose of this thesis was to study the mechanism and initiation of amyloid
formation as well as the spread of cerebral amyloidosis in vivo. The first series of
studies were conducted to define the role and contribution of extracellular versus
intracellular b-amyloid in plaque formation. To this end, we transplanted embryonic
wildtype (wt) and APP23 transgenic (tg) brain tissue into the hippocampus and cortex
of both APP23 and wt mice. We observed that APP23 grafts into wt hosts did not
develop amyloid deposits up to 20 moths post-grafting. In contrast, both tg and wt grafts
7into APP23 hosts developed amyloid plaques already 3 months post-grafting. The
amyloid deposits in wt grafts were surrounded by neuritic changes and gliosis similar to
the amyloid-associated pathology described in APP23 mice as well as in AD patients.
These results suggest that the phenotype of the transplanted tissue is strongly influenced
by the properties of the host. Moreover, these results provide evidence that diffusion of
Ab in the extracellular space is important for the spread of Ab pathology, that amyloid
formation starts extracellularly and that it is the extracellular amyloid that causes
neurodegeneration.
The second set of experiments were performed to study the initiation of amyloid
deposition and to clarify which factors are involved in the seeding process in vivo. Since
seeded polymerization of Ab has already been demonstrated in vitro and in vivo, we
replicated and advanced these findings by intracerebral injection of diluted brain extract
from AD patients and brain extracts from aged APP23 transgenic mice into young pre-
depositing APP23 mice. AD and APP23 brain homogenate induced a similar amount of
seeded Ab deposits in the brain parenchyma and vessel walls four month post-infusion.
This seeding was time- and concentration-dependent. In contrast, no seeding was
observed when PBS was injected or when the same extract was injected into wt mice.
To address whether Ab itself is the seeding agent we injected synthetic Ab into young
APP23 mice. These synthetic Ab injections resulted in limited Ab deposition compared
to that obtained with Ab-rich brain extract. Our findings suggest that Ab-containing
human and mouse brain extracts can induce cerebral amyloidosis in vivo, and that Ab,
in combination with additional factors, initiates amyloid formation.
The third part of the work presented here follows up on our previous finding that
diffusion of Ab in the extracellular space plays an important role in the spread of
cerebral amyloidosis. Therefore, we came up with the hypothesis that amyloid
deposition and the accompanied pathophysiology could influence extracellular space
(ECS) volume and interstitial fluid (ISF) diffusion properties. By using diffusion
weighted magnetic resonance imaging (DWI), we determined the diffusion properties in
the brains of young and aged APP23 transgenic mice and control littermates. Our results
indicate that fibrillar amyloid formation and the associated gliosis are accompanied by a
decrease in the apparent diffusion coefficient (ADC), suggesting that both build a
8barrier for interstitial fluid diffusion. Thus, in elderly people, ADC measurements and
the assessment of diffusion properties in the ECS could serve as a biomarker to detect
pathological events in the brain of AD patients.
In summary, the studies presented herein have increased our understanding of the
mechanisms leading to protein aggregation and finally to neurodegeneration in a
transgenic mouse model. We have shown that factors other than local Ab production,
such as diffusion in the extracellular space, are important in determining whether
amyloid pathology will occur. Moreover, the results highlight the relevance of
extracellular Ab to the pathogenesis of the disease. It still remains an open question
whether Ab  itself is sufficient to initiate plaque formation, and if so, what
conformational form of Ab is required. Together, these studies provide insights into the
mechanisms and disease pathways which may lead to AD.
91. Introduction
1.1 Protein misfolding and aggregation in neurodegenerative diseases
The misfolding and aggregation of proteins is one of the major threats for living
organisms. The necessary information for a polypeptide chain to fold correctly into a
three-dimensional structure is encoded in its primary amino acid sequence (Anfinsen,
1973). Normally, protein folding is assisted by chaperones that help correct folding and
remove misfolded and malfunctioning proteins. However, under physiological
conditions of high protein concentrations and cellular crowding (van den Berg et al.,
1999; Minton, 2000) and especially at high temperatures, many proteins tend to form
stable insoluble aggregates (Jaenicke, 1995). Aggregation occurs when
folding/unfolding intermediates become trapped in partially misfolded states that
successively associate, mainly through hydrophobic interactions, into an oligomeric
continuum of increasingly larger, more stable, and less soluble complexes.  In the
aggregated state, inactive proteins are enriched in anti-parallel b-strands (Fink, 1998).
They can appear as amorphous structures like inclusion bodies, or as ordered fibers
(straight, unbranched, 10-nm wide fibrils) such as amyloid plaques and prion particles
(Prusiner, 1998; McLaurin et al., 2000).
Age-related neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s
Disease (PD), Huntington’s Disease (HD), amyotrophic lateral sclerosis (ALS) and
transmissible spongiform encephalopathies (TSE) form a pathologically diverse group
that can affect thinking, skilled movements, emotion, cognition, memory and other
abilities (Table 1). However, despite their differences in clinical symptoms and disease
progression, these disorders do share some common features: most of them appear later
in life and their pathology is characterized by neuronal loss and synaptic abnormalities
(Martin, 1999). The hallmark feature of these conformational disorders is that proteins
can fold into an alternative stable conformation, which results in its aggregation and
accumulation as fibrillar deposits (Carrell and Lomas, 1997; Dobson, 1999). Insoluble
aggregates of disease related proteins are deposited as inclusions or plaques, the
characteristics of which are often disease specific. In AD, amyloid plaques are
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deposited in the brain parenchyma and vessel walls, composed mainly of the amyloid-b
protein (Glenner et al., 1984). In patients with PD, aggregates called Lewy bodies
deposit in the substantia nigra (Forno, 1996), with the major constituent being a-
synuclein (Spillantini et al., 1997). Intranuclear deposits of a polyglutamine-rich version
of huntingtin protein are typical for the brains of HD patients (DiFiglia et al., 1997). In
ALS, patients have aggregates that are mainly composed of superoxid-dismutase in the
cell bodies and axons of motor neurons (Bruijn et al., 1998). Finally, the brains of
humans that have been affected by TSE are characterized by aggregates of the prion
protein (PrP) (Bolton et al., 1982).
Disease Clinical
features
Protein
deposits
Toxic
protein
Affected brain
regions
Disease
gene
Alzheimer’s
Disease
Progressive
dementia
Extracellular
plaques
Intracellular
tangles
Amyloid-b
and Tau
Hippocampus,
cerebral
cortex
APP
PS 1
PS 2
Parkinson’s
Disease
Movement
disorder
Lewy bodies a-Synuclein Substantia
nigra,
hypothalamus
a-Synuclein
Parkin
UCHL1
Huntington’s
Disease
Dementia,
motor and
psychiatric
problems
Nuclear and
cytoplasmic
inclusions
Huntingtin Striatum,
cerebral
cortex
IT-15
Amyotrophic
lateral sclerosis
Movement
disorder
Bunina
bodies
Superoxide
dismutase
Motor cortex,
brainstem
SOD1
Transmissible
spongiform
encephalopathies
Dementia,
ataxia,
psychiatric
problems
Prion plaque Prion
protein
Various
regions
depending on
disease
PRNP
Table 1. Clinical and pathological features of neurodegenerative disorders
characterized by aggregation and deposition of abnormal protein (adapted from
Soto, 2003).
Although these cerebral aggregates have been recognized as a typical feature of
neurodegenerative diseases for many years, neuropathological studies have been unable
to determine whether they are directly involved in the pathogenesis of the disease.
Analysis of post-mortem tissue shows only a poor correlation between the amyloid
deposit load and the severity of clinical symptoms (Terry et al., 1991; Gutekunst et al.,
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1999). Moreover, the appearance of protein deposits in clinically normal, healthy,
elderly people (Katzman et al., 1988) question the role of protein aggregates in
neurodegeneration, even though protein aggregates accumulate mainly in the brain areas
that show degeneration. Support for a causal role of protein misfolding in
neurodegenerative diseases has come more recently from genetic studies since
mutations in the respective fibrillar proteins have been found in AD, PD, HD, ALS and
TSE (Hsiao et al., 1990; Goate et al., 1991; Group, 1993; Rosen et al., 1993;
Polymeropoulos et al., 1997). Furthermore, the generation of transgenic animal models,
which express mutant proteins, has provided good evidence for the contribution of
protein misfolding to the disease pathogenesis. Several pathological and clinical
features have been observed in transgenic models in which protein aggregates were
successfully produced (Hsiao et al., 1990; Gurney et al., 1994; Games et al., 1995;
Mangiarini et al., 1996; Davies et al., 1997; Masliah et al., 2000). AD may therefore be
seen as one example of many neurodegenerative diseases in which an abnormally
folded molecule accumulates in the brain and causes neuronal damage.
1.2 Alzheimer’s disease
It is almost a hundred years ago since the German psychiatrist Alois Alzheimer (1864-
1915) first described the clinical and pathological symptoms of the disease that now
bears his name. At a meeting in 1906, he first presented the case of a 54 year old
women who suffered from progressive dementia. Although his presentation of the
typical clinical and morphological features of AD was not considered to be worthy of
discussion at this time, it was published one year later (Alzheimer, 1907). The clinical
manifestations of the disease consist of progressive memory loss, disordered cognitive
function as well as altered behavior including paranoia, delusions, impairments of
attention, perception, reasoning and comportment, and a progressive decline in language
function (Price et al., 1993; Morris, 1996). Motor functions remain initially intact but
deteriorate in the final phase of the disease leading to a picture resembling motor
disorders such as parkinsonism (Selkoe, 2001). Mental functions and activities of daily
living become progressively impaired (Forstl and Kurz, 1999). A state of dementia
becomes identified when these deficits undermine the capacity for independent living.
The onset of the dementia in AD is preceeded by a transitional preclinical period of
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many years during which relatively isolated memory difficulties exceed those expected
on the basis of normal aging, without however, becoming severe enough to interfere
with daily living activities (Linn et al., 1995; Fox et al., 1998). Even normal aging does
not necessarily imply that memory function has remained intact (Small et al., 1999).
AD is the most common form of dementia in the elderly accounting for over 50% of the
typical, late-onset cases of dementia. The estimated number of patients is approximately
20 million worldwide and is expected to keep growing as the current population ages.
Epidemiological studies on the prevalence of AD estimate that not more than 10% of
the population over 65 years but 25% of the people over 80 years of age are affected
with AD (Pfeffer et al., 1987; Bachman et al., 1992; Lautenschlager et al., 1996; Hy and
Keller, 2000). Problems with memory and cognition appear during the seventh decade
in most individuals with AD, but may appear earlier, particularly in familial cases
(FAD)(Albert and Drachman, 2000). The largest proportion of AD cases are sporadic,
occurring with no clearly defined etiology. However, it has been known for several
decades that AD can occur in a familial form that is autosomal dominant inherited.
Estimates of the proportion of Alzheimer cases that are genetically based varied from as
low as 5% to as high as 15% (Selkoe, 1994; Lendon et al., 1997). Familial AD (FAD) is
clinically and pathologically indistinguishable from sporadic AD, except for the early
age of onset (Lehtovirta et al., 1996; Lippa et al., 1996).
1.2.1 Neuropathological hallmarks
The brains of AD patients contain two hallmark pathological features: neurofibrillary
tangles (NFT) and neuritic plaques. Classical senile or neuritic plaques are multicellular
lesions containing extracellular deposits of amyloid-b  protein (Ab) that include
abundant amyloid fibrils (7-10 nm) intermixed with non-fibrillar forms of the Ab
peptide. Neuritic plaques are surrounded by variable numbers of dystrophic neurites,
both axonal terminals and dendrites. Many such plaques contain activated microglial
cells situated near the amyloid core, as well as reactive astrocytes around the periphery
of the plaque (Itagaki et al., 1989; Wisniewski et al., 1989). Although many plaques
with these features can be found in the AD brain, an even larger number of deposits
seem to lack surrounding dystrophic neurites or glia. These lesions are called diffuse or
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preamyloid plaques, where the Ab occurs in a non-fibrillar, less dense and amorphous
form in the neuropil (Tagliavini et al., 1988; Yamaguchi et al., 1988; Yamaguchi et al.,
1989). In brain regions that are generally not implicated in the clinical syndrome of AD,
such as cerebellum, striatum and thalamus, almost all Ab deposits are diffuse with little
or no glial and neuritic reactions (Joachim et al., 1989; Ogomori et al., 1989;
Yamaguchi et al., 1989). Besides diffuse and compact plaques, extracellular Ab
deposits often occur in another morphological form in AD, in the walls of cerebral and
leptomeningeal blood vessels (Mandybur, 1975; Vinters et al., 1988). According to the
amyloid cascade hypothesis, accumulation and deposition of Ab in the brain is the
primary influence and early process driving AD pathogenesis leading to neuronal
dysfunction (Hardy and Higgins, 1992).
Increasing attention is turning towards small oligomeric aggregates that form initially
before they assemble into fibrils or plaques (Fig. 1). These oligomeric Ab assemblies
intermediates are potent neurotoxins and therefore are thought to be the key effectors of
neurotoxicity in AD (Klein et al., 2001). Importantly, such oligomeric forms of Ab are
neurotoxic in vitro (Oda et al., 1995; Walsh et al., 1997; Lambert et al., 1998; Hartley et
al., 1999; Walsh et al., 1999; Nilsberth et al., 2001) and in vivo (Walsh et al., 2002). In
transgenic mice expressing the human APP, neurological deficits develop even before
amyloid deposits occur (Mucke et al., 2000). It has been shown recently that oligomers
of Ab even inhibit long-term potentiation in vivo (Walsh et al., 2002). Another
intermediate in the pathway of Ab fibril formation is the protofibril. Protofibrils are
short assemblies of 5 nm in diameter and up to 200 nm in length (Harper et al., 1997;
Walsh et al., 1997). They are not only important in terms of amyloid fiber formation but
also in causing neuronal cell death (Hartley et al., 1999; Walsh et al., 1999). The role of
these intermediates in amyloid fiber assembly will be discussed further in section 1.3.2.
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Figure 1. Model of Ab assembly via nucleation-dependent polymerization.
Monomers form via several steps an unstable oligomeric nucleus. Once the critical
protein concentration is reached, seeded growth starts and generates amyloid fibrils via
protofibrils. This direct pathway may not be the only one since the addition of
monomers or paranuclei to protofibrils could also lead to the maturation into fibrils
(adapted from Harper and Lansbury, 1997; Bitan et al., 2003).
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Neurofibrillary tangles are intraneuronal cytoplasmic lesions consisting of
hyperphosphorylated isoforms of the microtubule-associated protein tau, which
assemble into poorly soluble paired helical 10-nm filaments (Goedert, 1998). Six tau
isoforms are produced in the adult human brain by alternative mRNA splicing from a
single gene located on chromosome 17 (Goedert et al., 1989; Andreadis et al., 1992).
The six resulting polypeptides have a molecular mass ranging from 45kDa to 65kDa
(Buee et al., 2000). Neurofibrillary tangles generally occur in large numbers in the AD
brain, particularly in limbic and paralimbic structures such as the entorhinal cortex,
hippocampus and amygdala. Intensive studies have shown that the tau protein, which
normally enhances the polymerization of tubulin into microtubules and acts to stabilize
these organelles in neurons, becomes excessively phosphorylated which reduces
binding to microtubules (Lovestone and Reynolds, 1997). The tau and tangle hypothesis
argues that in AD the normal role of tau in stabilizing microtubules is impaired, and in
diseased neurons microtubules are replaced by tangles (Gray et al., 1987). The resultant
cytoskeletal dysfunction in these neurons eventually leads to the degeneration of
dendrites and a loss of synapses at their axonal projection targets. The observation that
neurofibrillary tangles form in some cell bodies whose axons terminate in regions
containing amyloid-bearing neuritic plaques suggests that neurofibrillary tangle
formation in some perikarya and neurites may be related to events associated with
amyloid plaque formation in the AD brain (Hyman et al., 1986; Rasool et al., 1986).
In addition to plaques and tangles, the AD brain is characterized by extensive neuronal
degeneration. The cortex and hippocampus of AD patients undergo a marked atrophy
(Mouton et al., 1998), region specific neuron and synapse loss (Terry et al., 1991; West
et al., 1994; Gomez-Isla et al., 1996) and a loss of cholinergic innervation (Coyle et al.,
1983). Yet, despite intensive interest in a potential association between the tangles,
amyloid plaques, vascular amyloid and neurodegeneration observed in the AD brain, the
relationship remains poorly understood.
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1.2.2 Genetics of Alzheimer’s disease
While the complete etiological picture of AD remains unresolved, the inheritance of
predisposing genetic factors appears to play a major role. After age, family history is the
second greatest risk factor for AD. To date, three genes have been identified whose
mutations cause early-onset familial AD (FAD). These genes are the amyloid precursor
protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) (Schellenberg, 1995). Studies
on the amyloid precursor protein (APP) as a genetic determinant of AD have begun
with the observation that individuals with Down’s syndrome develop the clinical and
pathological features of AD (Mann et al., 1985; Mann, 1988). These data pointed to the
involvement of chromosome 21 in AD leading to the first genetic linkage discovery
between a locus on chromosome 21q and autosomal dominant early-onset familial AD
(St George-Hyslop et al., 1987). Sequencing of the APP gene and screening for
mutations led to the discovery of several missense mutations in families with early-
onset AD (Goate et al., 1991; Hendriks et al., 1992; Mullan et al., 1992). Although the
APP mutations account for less than 0.1% of all AD cases (Tanzi and Bertram, 2001),
they carry virtually complete penetrance leading to AD between the fourth and seventh
decades of life.
Since most early–onset AD families do not have mutations in the APP gene, it was
expected that other AD loci might exist. A second locus was linked to chromosome 14,
and the gene was later identified and named presenilin 1 (PS1) (Van Broeckhoven et al.,
1992; Sherrington et al., 1995). A second gene was found based on its homology to PS1
and mapped on chromosome 1 (Levy-Lahad et al., 1995b; Levy-Lahad et al., 1995a;
Rogaev et al., 1995). Mutations in these two genes (PS1 and PS2) are thought to cause
up to 80% of familial early-onset AD cases. To date there are more than 120 different
mutations identified in the PS1 gene (http://molgen-www.uia.ac.be/ADMutations),
while only 8 missense mutations have been identified in PS2. Early-onset familial AD
mutations in PS1, PS2 and APP lead to an increase of secreted Ab42, the primary
component of b-amyloid plaques in the brain (Price and Sisodia, 1998; Haass and De
Strooper, 1999).
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In addition to the mutations that have been associated with early-onset FAD, other
genetic factors have been identified that increase the risk of developing sporadic AD.
The e4 allele of the apolipoprotein E (APOE) gene on chromosome 19 (Olaisen et al.,
1982) was first discovered as a major risk factor for AD (Strittmatter et al., 1993a). In
humans there are three common alleles of the APOE gene: e2, e3 and e4.  APOE
normally plays a role in cholesterol transport and lipid metabolism (Mahley, 1988;
Vancea et al., 2000). While the e4 allele is strongly associated with increased neuritic
plaques and cerebral amyloid angiopathy in AD (Olichney et al., 1996), the e2 allele has
been shown to have an impact on longevity and may confer protection against AD
(Corder et al., 1994). Distinct binding properties to the Ab peptide (Strittmatter et al.,
1993b) have suggested ways by which APOE might mediate its action. Less than 50%
of non-familial AD cases are carriers of the APOEe4 allele (Corder et al., 1993)
suggesting that other susceptibility genes must be involved in the pathogenesis of the
disease (Shastry and Giblin, 1999). Most of these genes are located on chromosome 9,
10 and 12 (Okuizumi et al., 1995; Ertekin-Taner et al., 2000; Lambert et al., 2000) and
are proteolytic enzymes, plasma proteins, growth factors or membrane receptors such as
a2-macroglobulin (a2-M) (Blacker et al., 1998), low density lipoprotein receptor-
related protein (LRP) (Okuizumi et al., 1995), angiotensin converting enzyme (ACE)
(Kehoe et al., 1999) and insulin degrading enzyme (IDE) (Bertram et al., 2000; Ertekin-
Taner et al., 2000). a2-M is thought to mediate the clearance and IDE has been
implicated in the degradation of Ab peptides (Vekrellis et al., 2000).
Thus, all AD genetic factors discovered so far point to an alteration of Ab production or
clearance as a direct cause of the disease.
1.2.3 APP processing and Ab
The isolation of Ab from senile plaques and cerebrovascular deposits of AD brains
(Glenner and Wong, 1984; Masters et al., 1985) and the cloning of the full-length
cDNA of APP (Kang et al., 1987) were the beginning of the modern AD research era.
APP is a type-I integral transmembrane glycoprotein that is ubiquitously expressed.
Three major isoforms of APP are produced by alternative splicing: the two longer
isoforms of 751 and 770 amino acids contain a protease inhibitor domain (Kitaguchi et
al., 1988; Ponte et al., 1988; Tanzi et al., 1988), whereas the shorter form of 695 amino
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acids lacks this Kunitz domain and is the main isoform expressed in neurons (Kang et
al., 1987; Golde et al., 1990). The physiological function of APP in the brain remains
unclear, although it has a putative function in transmembrane signal transduction
(Nishimoto et al., 1993), calcium regulation (Mattson et al., 1993), cell proliferation
(Saitoh et al., 1989), regulation of cell/cell or cell/matrix interactions (Breen et al.,
1991), cell-adhesion (Jin et al., 1994), neurite outgrowth (Milward et al., 1992) and
synaptogenesis (Mucke et al., 1994). Initial studies of APP knockout mice did not
reveal an obvious disease phenotype (Zheng et al., 1995), however, other studies have
suggested cognitive deficits (Dawson et al., 1999; Phinney et al., 1999) and impaired
synaptic plasticity (Seabrook et al., 1999).
APP can be processed by several different proteases, namely the a-, b- and g-secretases
(Fig. 2). The a-secretase cleavage pathway corresponds to the default secretory pathway
and is considered as non-amyloidogenic. a-secretase cleaves within the Ab region to
produce the soluble a-APPs (Esch et al., 1990; Sisodia, 1992) and the 83-residue
COOH-terminal fragment C83. The identity of the a-secretase is unknown, although
more than one enzyme may be involved as the preferential cleavage site varies in
different cell types (Zhong et al., 1994). TACE, ADAM-10 and MDC-9, which all
belong to the family of adamlysines have been postulated as a-secretase candidates
(Buxbaum et al., 1998; Koike et al., 1999; Lammich et al., 1999; Lopez-Perez et al.,
2001). The b-secretase cleavage corresponds to the alternative cellular pathway that
process APP and constitutes the first step in the formation of Ab peptides. In contrast to
the a-secretase, the b-secretase generates the NH2-terminus of Ab, cleaving APP to
produce a soluble version of APP and C99 which remains membrane-bound (Seubert et
al., 1993). Two novel aspartyl protease homologous, BACE and BACE-2 were recently
identified that cleave APP at the b-secretase sites (Sinha et al., 1999; Vassar et al.,
1999). In addition, genetic experiments have demonstrated that BACE is required for
Ab peptide formation, confirming its identity as the b-secretase gene (Cai et al., 2001;
Luo et al., 2001). Both the C83 and C99 fragments remain anchored in the membrane
and may become degraded or further processed by g-secretase to produce p3 from C83
or Ab from C99. The g-secretase cleavage is not sequence specific and can produce a
variety of Ab peptides. Ab40 is the most common Ab peptide, while Ab42 is the
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second most common form. The longer the peptide the more insoluble it gets and the
more likely it is to form toxic fibrils and aggregates (Jarrett et al., 1993b). The identity
of the g-secretase remains elusive. However, it has been proposed that g-secretase forms
a large complex composed of presenilin, nicastrin, PEN-2, and APH-1, and that the
activity of the g-secretase depends on these proteins (Steiner and Haass, 2000; Yu et al.,
2000; Francis et al., 2002; Lee et al., 2002; Steiner et al., 2002). Most recent studies
have shown that APP is cleaved by PS-dependent g-secretase not only in the middle of
the transmembrane domain (g-cleavage) but also inside the cytoplasmic membrane
boundary (e-cleavage) (Gu et al., 2001; Sastre et al., 2001; Yu et al., 2001a; Weidemann
et al., 2002). However, the functional significance of e-secretase cleavage remains to be
clarified.
Many different pathogenic mutations such as Swedish (Mullan et al., 1992), Flemish
(Hendriks et al., 1992), Dutch (Levy et al., 1990), Florida (Eckman et al., 1997) and
London (Goate et al., 1991) have been identified in APP, all of which are missense
mutations lying at the three secretase cleavage sites or within the Ab region, as shown
in Figure 2. AD-causing mutations in APP near the b-and g-secretase cleavage sites all
increase Ab42. Those near the b-secretase cleavage site augment b-site proteolysis,
leading to elevation of both Ab40 and Ab42 (Citron et al., 1992), whereas those near
the g-site increase the production of Ab42 (Suzuki et al., 1994).
While Ab40 is the major Ab product of APP processing and the major component of
the amyloid deposits of congophilic angiopathy (Joachim et al., 1988; Miller et al.,
1993; Gravina et al., 1995),  Ab42/43 has a much greater tendency to aggregate
spontaneously into amyloid fibrils (Hilbich et al., 1991; Burdick et al., 1992; Jarrett and
Lansbury, 1993) and is the predominant form of Ab in senile plaque cores (Roher et al.,
1993; Fukumoto et al., 1996). In addition, Ab42 displays enhanced neurotoxicity
relative to Ab40 (Younkin, 1995; Selkoe, 1999; Dahlgren et al., 2002). Interestingly,
Ab42 levels are reduced in the cerebrospinal fluid (CSF) of AD patients (Motter et al.,
1995), which has been attributed to reduced clearance. Taken together, these findings
implicate Ab42 in the pathogenesis of AD. The development of antisera specific for
Ab40 and for Ab42 enabled plaque evolution and composition to be studied
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systematically (Iwatsubo et al., 1994; Gravina et al., 1995). The results are consistent
with a nucleation or seeding hypothesis (Jarrett et al., 1993a; Jarrett and Lansbury,
1993), whereby Ab42 forms the nucleus of a plaque initially, leading to the subsequent
deposition of soluble Ab40 (Iwatsubo et al., 1994). The seeding model and its role in
the pathogenesis of AD will be described in section 1.3.2.
Figure 2. Proteolytic processing of APP. APP is a 770 amino acid type I
transmembrane protein which is cleaved by different proteases. The initial cleavage by
a-secretase is the most common cleavage, resulting in the release of the large
extracellular domain. Since the a-secretase cleavage is in the middle of the Ab domain,
no Ab can be generated. Instead, the remaining fragment (C83) is cleaved by g-secretase
and releases the small peptide p3. Less frequently, APP is cleaved by b-secretase and
then in the transmembrane domain either at position 40 or 42 by g-secretase. This b-
secretase pathway is the first step in the formation of Ab peptides and amyloid. There
are many APP mutations known that cause familial AD. Note that these mutations are
localized within the Ab domain near the cleavage sites of the secretases.
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1.2.4 Mouse models of Alzheimer’s disease
The identification of mutations in specific genes has provided new opportunities to
explore pathogenic mechanisms using genetically engineered mice. To generate animal
models of Ab amyloidosis, many groups have produced transgenic mice that express
wild-type APP, APP fragments, Ab and FAD linked mutant APP and PS1. Although
early efforts were disappointing because transgenic mice did not exhibit abnormalities
characteristic of AD, more recent work has shown that multiple lines of APP transgenic
mice now exist that develop age-related deposition of cerebral amyloid similar to AD
(Games et al., 1995; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997). These mice have
mild neuron loss, dystrophic neurites, glial responses, learning impairments and deficits
in synaptic transmission and/or long-term potentiation (Hsiao et al., 1996; Irizarry et al.,
1997; Calhoun et al., 1998; Frautschy et al., 1998; Chapman et al., 1999; Stalder et al.,
1999; Bondolfi et al., 2002; Kelly et al., 2003). The disease severity is influenced by the
level of transgene expression and the specific mutation. This is in line with the
observation that mice expressing both mutant PS1 and mutant APP showed accelerated
Ab amyloidosis well before APP transgenic mice (Borchelt et al., 1997; Holcomb et al.,
1998). APP transgenic mice have also been crossed with mice deficient in APOE. In
contrast to the APP/PS1 double transgenic mice, these mice show a remarkable decrease
in congophilic plaques, suggesting that APOE promotes the deposition and fibrillization
of Ab (Bales et al., 1997; Holtzman et al., 2000).
As APP transgenic models failed to develop tau filaments, several research groups have
generated human wildtype tau transgenic mice (Gotz et al., 1995; Brion et al., 1999;
Ishihara et al., 1999; Spittaels et al., 1999; Probst et al., 2000). However, none of these
transgenic mice developed tau filaments. Only one group reported that their human
wildtype tau transgenic mice developed tangle like structures at high age (Ishihara et al.,
2001). The expression of P301L mutation was more successful in terms of pathology
since these tau transgenic mice showed numerous neurofibrillary tangles (Lewis et al.,
2000; Gotz et al., 2001b).
However, appropriate mouse models that display the entire neuropathological spectrum
of AD have so far not been entirely successful (Wong et al., 2002). In an attempt to
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obtain mice with both plaques and tangles, APP transgenic mice were breed with mice
expressing the P301L mutant tau. Although the NFT pathology was substantially
enhanced, plaque formation was unaffected by the presence of the tau lesions (Lewis et
al., 2001). Similarly, tau pathology can be induced by introducing Ab42 fibrils into
P301L tau mutant mice (Gotz et al., 2001a). Together, both experiments demonstrated
pathological interactions between Ab and tau that lead to increased NFT formation.
Recently, triple-transgenic mice (PS1, APP and P301L) have been created that develop
extracellular Ab deposits prior to tangle formation in AD relevant brain regions (Oddo
et al., 2003). However, more appropriate models of AD might require co-expression of
mutant APP and all six isoforms of wildtype human tau.
In an effort to understand the functions of the AD related genes, researchers have
ablated most of them. As mentioned above, homozygous APP -/- mice show only a
subtle phenotype (Zheng et al., 1995). PS1-/- mice fail to survive beyond the early
postnatal period, but exhibit severe problems in the development of the axial skeleton
and ribs (Shen et al., 1997). The lack of PS1 expression in the forebrain in conditional
PS1-targeted mice resulted in decreased Ab generation, further establishing that PS1 is
critical for g-secretase activity in the brain (Feng et al., 2001; Yu et al., 2001b). BACE1
-/- mice are healthy and have also no obvious phenotype, but secretion of Ab peptides is
abolished suggesting that BACE1 is the principal b-secretase in neurons (Cai et al.,
2001; Luo et al., 2001; Roberds et al., 2001).
1.2.5 Therapeutic approaches
According to the amyloid cascade hypothesis, the accumulation of Ab42 in certain brain
regions is an early and critical event in the pathogenesis of AD (Hardy and Selkoe,
2002). Therefore, anti-amyloid strategies are currently being investigated to lower the
production of Ab (either by inhibiting b- and g-secretases or by favouring the a-
secretase pathway over the b-secretase pathway), or to clear the amyloid peptides by the
use of defibrillating agents or by immunization (Fig. 3).
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Figure 3. Summary of the main pathological processes and the related therapeutic
approaches in AD. These approaches target the pathogenesis of the disease such as
APP processing, amyloid plaques and inflammation. The treatment strategies include b-
and g-secretase inhibitors, a-secretase enhancers, cholesterol-lowering drugs and
NSAIDs but also amyloid-b-peptide vaccination, b-sheet breakers and metal chelators
(adapted from Scarpini et al., 2003).
The b-secretase BACE is thought to be an ideal therapeutic target as it catalyses the first
step of Ab production. Inhibitors described so far are polypeptides that are effective in
vitro (Sinha et al., 1999; Ghosh et al., 2001), however, these peptidic compounds do not
penetrate the blood-brain barrier to a sufficient extent (Citron, 2002). g-secretase also
represents a potential therapeutic target. Potent inhibitors have recently been developed
that are effective in preventing the formation of both Ab40 and Ab42 (Wolfe et al.,
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1999; Esler et al., 2000; Seiffert et al., 2000; Shearman et al., 2000; Dovey et al., 2001).
However, a limitation to the use of g-secretase inhibitors may be that they interfere with
Notch signaling and possibly other cellular functions (De Strooper et al., 1999). A
recent report that described compounds that inhibit Ab formation without affecting
Notch cleavage may offer new leads for the design of APP-specific g-secretase
inhibitors (Petit et al., 2000). It has also been shown that g-secretase inhibitors reduce
amyloid burden in animal models (Dovey et al., 2001). A subset of non-steroidal anti-
inflammatory drugs (NSAIDs) are allosteric inhibitors of g-secretase (Weggen et al.,
2001). This effect was independent of the intended effect of the NSAIDs, namely
cyclooxygenase inhibition. Metabolism by a-secretase can be stimulated by the
activation of several cell-surface receptors coupling to protein kinase C (Lee et al.,
1995). Estrogens and testosterone were found to promote a-secretase cleavage of APP
in cell culture and to reduce Ab formation. Thus, hormone replacement therapy may
have positive effects in preventing AD. Estradiol treatment is currently being
investigated in animal models (Petanceska et al., 2000). In vitro and in vivo experiments
have proposed a molecular link between AD and cholesterol (Simons et al., 1998;
Frears et al., 1999; Puglielli et al., 2001). High cholesterol uptake increased Ab
deposition in transgenic mice and in rabbits (Sparks et al., 1994; Refolo et al., 2000). It
has also been shown in animals that a cholesterol synthesis inhibitor reduced plaque
formation in transgenic mice (Refolo et al., 2000). Therefore, cholesterol lowering
drugs such as simvastatin could be an attractive treatment strategy for AD (Fassbender
et al., 2001).
Another approach to reduce amyloid accumulation and toxicity in AD is the use of
chemical agents that prevent Ab oligomerization and the formation of neurotoxic
protofibrils. A variety of compounds including Congo red (Lorenzo and Yankner,
1994), rifampicin (Tomiyama et al., 1996) and benzofurans (Soto, 1999) have been
proposed but are not applicable in vivo due to their toxicity. The design of short
synthetic peptides homologous to the central hydrophobic region of Ab has been
suggested to disrupt b-sheet stabilisation (Soto, 2001). Administration of this b-sheet
breaker reduced the plaque load and ameliorated astrogliosis, microglial activation as
well as neurodegeneration in APP transgenic mice (Permanne et al., 2002). Moreover,
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this peptide did not induce antibody production and could cross the blood-brain barrier.
Serum amyloid P component (SAP) is a glycoprotein that is present in amyloid deposits
and seems to protect amyloid fibrils from degradation and clearance (Tennent et al.,
1995). Recently, a small compound has been developed that dimerizes SAP, reduces its
concentration in the plasma and destabilizes Ab deposits in vivo (Pepys et al., 2002).
Oligosaccharide (Fraser et al., 2001) and metal chelators (Cherny et al., 1999; Cherny et
al., 2000) can also inhibit plaque formation and constitute potential plaque busters. The
administration of clioquinol to transgenic mice reduced Ab deposition (Cherny et al.,
2001).
Apart from the prevention of plaque formation, the removal of deposited plaques has
become possible through immunotherapeutic approaches. Transgenic mice have been
successfully immunized either by active or passive immunization against Ab (Schenk et
al., 1999; Bard et al., 2000). This vaccination not only prevents the development of Ab
plaques, neuritic dystrophy and astrogliosis, but also markedly reduces the extent and
progression of AD-like pathology. Importantly, further studies revealed that such
vaccination can improve learning and memory deficits (Janus et al., 2000; Morgan et
al., 2000; Younkin, 2001; Dodart et al., 2002). However, a recent phase IIa clinical trial
for an AD vaccine (AN-1792) was stopped when 17 of 360 patients developed severe
inflammatory side effects. One of the trial participants developed leptomeningeal
infiltrates around amyloid-laden blood vessels with T lymphocytes (Nicoll et al., 2003).
In summary, the development of anti-Ab therapeutics remains a rational approach to
treat AD, based on our current understanding of the earliest features of the disease.
Despite all difficulties, current data from various laboratories indicates that Ab-targeted
therapy is the most likely to be effective in reducing amyloid-related pathology in AD.
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1.3 Studying cerebral amyloidosis in vivo
1.3.1 Intracerebral grafting
Grafting tissue into the brain as a possible therapy for neurodegenerative disease has
been of enormous interest for many scientists in the past and present research.
Parkinson’s patients especially have benefited from such therapeutic approaches
(Bjorklund, 1991; Freed et al., 1992; Lindvall et al., 1992; Freed et al., 1993; Koutouzis
et al., 1994). What is often ignored is the enormous benefit grafting techniques can
provide basic research with. For many scientists, intracerebral grafting is a tool used to
learn more about neuronal plasticity of the adult nervous system, and as a technique to
establish principles of neuronal development. To these ends, intracerebral grafting is
established as a powerful method to study basic problems in neuroscience (Fig. 4).
Figure 4. Schematic diagram of the transplantation procedure. Cortical and
hippocampal tissue is dissected from E16-17 embryos and then mechanically
dissociated into a cell suspension. Several 2.5 ml aliquots of this cell suspension are
stereotactically injected via a microsyringe into the neocortex and hippocampus of the
host animal. Histological analysis are performed after different time points.
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Many important issues concerning the biological requirements for graft survival and
optimal function of the graft have been identified. It has been postulated that for most
donor tissues, the younger the cells are, the better their chance of survival (Gage et al.,
1983; Brundin et al., 1985; Barker et al., 1995). This is particularly true for neuronal
tissue, which explains the focus of attention on fetal cells in intracerebral grafting. An
equally important factor is the age of the host brain. While grafts will survive in the
adult and aged brain (albeit less well in the aged brain), significantly better survival is
observed in the young neonatal brain. Both the limitations of donor age and host may be
attributed in part to the availability of trophic factors which can address specifically the
survival and growth of grafted tissue independently of many other issues (Gage et al.,
1984; Mayer et al., 1993). In order for a graft to survive and integrate in the brain, it
must be appropriately vascularized and thereby receive essential nutrients from the host
environment (Broadwell et al., 1987; Dusart et al., 1989).
While the above factors can be used to influence the survival of the graft, a major
objective is to establish graft function in the host brain. One such function is the
interaction with the host brain, which should provide at least partial replacement for
missing connections. Alternatively, the graft may serve as an endogenous minipump
which secretes a missing transmitter (Horellou et al., 1991; Campbell et al., 1993; Cenci
et al., 1994) or a trophic factor, which directly affect the survival and growth of
damaged cells (Gage et al., 1984). Finally, the graft can function as a bridge that
contributes to neuronal and axonal connections (Zimmer et al., 1986; Zimmer et al.,
1988).
Before grafting can be considered as a likely approach to cure Alzheimer’s disease, the
cause of this neurodegenerative disease needs to be determined. With the availability of
experimental animal models which mimic the pathological characteristics of the disease,
intracerebral grafting could be used to address the pathophysiology of AD. Therefore,
intracerebral grafting became a good tool to study the pathogenesis of plaque formation
and the underlying and associated pathology.
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1.3.2 Seeding mechanism
Kinetic studies have shown that the aggregation of Ab follows a seeding/nucleation
mechanism (Jarrett and Lansbury, 1993), which resembles a crystallization process. The
critical event is the formation of protein oligomers that act as a nucleus and which direct
further growth of aggregates. Nucleation-dependent polymerization involves two stable
states, the monomeric protein and the fibril (Harper and Lansbury, 1997). There is first
a slow nucleation phase in which the protein forms an ordered oligomeric nucleus and
then a growth phase in which the nucleus rapidly grows to form larger polymers.
Polymers are not observed until the monomer concentration exceeds a certain level
known as the critical concentration. Below this critical concentration, the monomer is
the predominant species. At protein concentrations that exceed the critical concentration
by a small amount, there is a lag time before polymerization occurs. During this lag
time, addition of pre-formed nuclei or seeds will immediately induce fibril formation.
This nucleation-dependent polymerization postulates that aggregation is dependent on
protein concentration and time.
At least two intermediates have been identified in this process from the native
monomeric protein to the fibrillar, fully aggregated structure in vitro (Teplow, 1998).
The first are soluble oligomers, which have been detected in test tube experiments, in
the medium of Ab secreting cells and in human cerebro-spinal fluid CSF and brain
homogenate (Levine, 1995; Kuo et al., 1996; Lambert et al., 1998; Walsh et al., 2002).
The second intermediates are short structures termed protofibrils, which have been
studied by electron microscopy and atomic force microscopy (Walsh et al., 1997; Walsh
et al., 1999). Protofibrils are 5 nm wide and up to 200 nm long. Protofibrils are the
direct precursor of amyloid-like fibrils. Secondary structure studies show that
protofibrils have a high b-sheet content like fibrils (Walsh et al., 1999). Evidence
indicates that these intermediates, the monomers, and the fibrils are all present in an
dynamic equilibrium (Teplow, 1998).
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1.3.3 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a special, non-invasive technique used to image
internal stuctures of the body, particularly the soft tissues. Unlike conventional
radiography and computed tomography (CT), which make use of potentially harmful X-
rays to generate images, MRI is based on the magnetic spin properties of atoms. In
essence, MRI produces a map of hydrogen distribution in the body. Hydrogen is the
simplest element known and the most abundant in biological tissues. It will align itself
within a strong magnetic field, like the needle of a compass. The earth’s magnetic field
is not strong enough to keep a person’s hydrogen atoms pointing in the same direction,
but the superconducting magnet of an MRI machine can. This comprises the “magnetic”
part of MRI. Once the hydrogen atoms have been aligned in the magnet, they absorb
energy emitted in the form of specific radio wave frequencies, which knocks them back
out of the alignment. Thus, the atoms alternately absorb and emit radio wave energy,
vibrating back and forth between their resting (magnetized) and their agitated (radio
pulse) state. This comprises the “resonance” part of MRI. The equipment records the
duration, strength, and source location of the signals emitted by the atoms as they relax
and translates the data into an image on a television monitor. The state of hydrogen in
diseased tissue differs from healthy tissue of the same type, making MRI particularly
good for the diagnosis of many disease processes due to high soft-tissue contrast and
discrimination.
Recent advances in MRI technology with high magnetic fields and the introduction of
transgenic mouse models of neurodegenerative diseases in MRI studies produced a
great interest for identifying alterations in cellular pathology. MRI can not only provide
high-resolution anatomical details on the distribution of the pathology but also
pathological information through additional parameters such as relaxion times, cerebral
blood flow (CBF) and apparent diffusion coefficient (ADC). As the change of ADC in
brain tissue was measured in one of the studies presented in this thesis, it will be briefly
discussed further. ADC describes the self-diffusion of water molecules, which is
characterized by Brownian motion in the restricted environment. In biological systems,
most of the diffusive motion of water molecules is restricted by the structures in the
microenvironment, including cell membranes. In many pathological conditions, ADC
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has been shown to be a very sensitive parameter reflecting changes in the cellular
environment including cell membrane disruption and cell swelling (Norris, 2001). A
more recent variant of diffusion MRI is diffusion tensor imaging (DTI) (Basser et al.,
1994), which is an important method to map and characterize white matter tracts in the
brain (Mori et al., 2001). This new technique uses the anisotropy of ADC. When water
molecules are unconstrained, as in the CSF, the diffusion is equal in all directions, i.e.,
isotropic. In contrast, when water molecules are in highly organized tissue structures,
such as white matter fiber tracts that restrict the self-diffusion of water, the resulting
diffusion is directional or so called anisotropic. DWI determines this anisotropy and
plays therefore an important role in the characterization of neuronal disease in humans
and in animal models (Kauppinen et al., 1993).
The recent technical advances of in vivo MRI, including the availability of higher
magnetic fields permitting improved spectral and spatial resolution are of great use to
examine morphological changes noninvasively. With the potential of MRI and the
availability of a number of transgenic and rodent models of neurodegeneration, we can
gain further understanding of the brain pathogenesis of neurodegenerative disorders and
the therapeutic strategies, which will eventually benefit humans.
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2.1 Abstract
Amyloid precursor protein (APP) processing and the generation of b-amyloid peptide
(Ab) are important in the pathogenesis of Alzheimer’s disease. While this has been
studied extensively at the molecular and cellular levels, much less is known about the
mechanisms of amyloid accumulation in vivo. We transplanted transgenic APP23 and
wildtype B6 embryonic neural cells into the neocortex and hippocampus of both B6 and
APP23 mice. APP23 transgenic grafts into wildtype hosts do not develop amyloid
deposits up to twenty months post-grafting. In contrast, both transgenic and,
surprisingly, wildtype grafts into young transgenic hosts develop amyloid plaques as
early as three months post-grafting. Although largely diffuse in nature, some of the
amyloid deposits in wildtype grafts were congophilic and were surrounded by neuritic
changes and gliosis similar to the amyloid-associated pathology previously described in
APP23 transgenic mice. Our results suggest that diffusion of soluble Ab  in the
extracellular space plays an important role in the spread of Ab pathology and that
extracellular amyloid formation can lead to neurodegeneration.
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2.2 Introduction
Alzheimer’s disease (AD) is a late onset progressive neurodegenerative disorder that is
characterized by aggregation of Ab into senile plaques and cerebrovascular amyloid.
Genetic studies and transgenic (tg) mice support the view that the production and/or
deposition of Ab is an early and critical process in AD pathogenesis that triggers a
cascade of pathological events leading to neurofibrillary tangle formation,
neuroinflammation, synapse and neuron loss, and dementia (Selkoe, 2001; Hardy and
Selkoe, 2002). A matter of controversy, however, is whether this cascade is initiated by
the accumulation of Ab in the extracellular space or by intraneuronal Ab generation
(Martin et al., 1994; Hartmann et al., 1997; Geula et al., 1998; Gouras et al., 2000; Kane
et al., 2000; Walsh et al., 2000; Bayer et al., 2001; D'Andrea et al., 2001; Selkoe, 2001;
Wirths et al., 2001).
In an attempt to study mechanisms and early stages of abnormal protein deposition and
related neurotoxicity, neural transplantation techniques have previously been applied to
study prion encephalopathy (Brandner et al., 1996b). In AD research, similar
approaches have been pursued, but no convincing amyloid pathology has been
associated with the grafts (Richards et al., 1991; Holtzman et al., 1992; Mantione et al.,
1995; Bayer et al., 1996). However, the recent generation of APP tg mice that develop
robust cerebral amyloid with aging (Games et al., 1995; Hsiao et al., 1996; Sturchler-
Pierrat et al., 1997) has opened new opportunities to study the mechanism of cerebral
amyloidosis by using neurografting techniques. To test the hypothesis that transplanted
neural tissue would retain its native properties regardless of host genotype, we
transplanted wildtype (wt) and APP tg embryonic cortical and hippocampal brain tissue
into the brains of both APP tg and wt mice. Our results suggest that the phenotype of
the transplanted tissue is strongly influenced by the properties of the host, and suggest a
key role of extracellular diffusion of Ab in cerebral amyloidogenesis. Moreover, we
conclude that extracellular amyloid formation is closely associated with
neurodegeneration.
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2.3 Results
APP23 grafts in B6 hosts do not develop amyloid up to 20 months post-grafting
Cell suspensions of APP23 tg embryonic cortical and hippocampal tissue were injected
into the neocortex and hippocampus, respectively, of young, 3 month-old B6 wt mice.
Grafts were analyzed 3-24 months later. All grafts integrated well into the surrounding
host tissue and appeared healthy and viable by morphological analysis. Only minimal
gliosis was found at the graft-host interface. Nevertheless, grafts could easily be
identified in cresyl-violet stained sections due to differences in cytoarchitecture between
graft and host tissue (Fig. 1A,D,G). Immunohistochemistry revealed robust and
exclusive expression of human APP (hAPP) in the graft, where hAPP was restricted to
neurons and their processes, consistent with the neuron-specificity of the Thy-1
promoter used to generate APP23 tg mice (Fig. 1B,E,H). Cellular hAPP expression
within the grafts looked very similar to that in adult APP23 mice.
Surprisingly, in light of the observation that amyloid deposition in neocortex and
hippocampus of APP23 mice starts at the age of 6 months (Sturchler-Pierrat et al.,
1997), no amyloid formation was observed in hippocampal or cortical grafts up to 20
months post-grafting (Fig. 1C,F and Table 1). Beyond 20 months, i.e. when hosts were
more than 23 months of age, we identified two out of nine mice that developed massive
amyloid in the parenchyma and vasculature within at least one graft (Fig. 1I).
Interestingly, some amyloid was found outside the grafts, in particular in vessels. To
study whether it is the age of the host or the post-grafting time that determines amyloid
deposition in the grafts, we also placed tg grafts in adult and aged wt hosts (Table 1).
Again, grafts appeared healthy, viable and, well integrated into the host. However, no
amyloid formation was observed in such grafts, suggesting that it is not the age of the
host but the time of the grafts residing in the host that determines amyloid formation.
APP expression and Ab levels in APP23 grafts
We have tested several hypotheses to explain the delay/lack of amyloid formation in
neocortical and hippocampal APP23 tg grafts in wt hosts compared to the cerebral
amyloidosis observed in APP23 mice at the age of 6 months. First, we have tested the
hypothesis that hAPP expression may be downregulated in grafted neurons compared to
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the expression in normal adult APP23 mice (Fig. 2A,B). However, no obvious
differences in hAPP expression were found in micropunches taken from neocortical and
hippocampal tg grafts compared to micropunches taken from neocortex and
hippocampus of normal adult APP23 mice.
Second, we tested the hypothesis that alterations in the processing of hAPP in grafted
neurons may lead to a reduction in Ab production and/or a shift in the ratio of Ab1-40
to Ab1-42. To this end, Ab was immunoprecipitated from micropunches taken from tg
grafts and compared to micropunches taken from 4-6 month-old APP23 mice, at an age
before these mice develop amyloid deposits. Results revealed similar Ab levels in the
grafts compared to young APP23 mice with a predominance of Ab1-40 over Ab1-42
(Fig. 2B). Differences of Ab1-40 levels in the grafts compared to young APP23 mice
ranged from –31% to +28% (mean –2% ± 17%; P > 0.05). Interestingly, in the oldest
transplant analyzed (20 months post-grafting), there was a relative increase of Ab1-42
compared to Ab1-40 (Fig. 2C). This observation is consistent with the result obtained in
aged amyloid-depositing APP23 mice. Overall, these results do not support the
hypothesis that reduced Ab production by the grafted tissue is responsible for the slow
onset of amyloid deposition in APP23 grafts in wt mice vs. normal APP23 mice.
Third, we have followed the hypothesis that intracerebral grafting of tg hAPP/Ab
producing tissue might evoke a humoral immune response in a wt host that has never
seen hAPP/Ab before (Brandner et al., 1996a), which might prevent amyloid deposition
in the transplant (Schenk et al., 1999). However, serum titers of anti-Ab antibodies in
engrafted mice were not different from serum titers of normal B6 mice (both < 1:100).
As a positive control we have used sera of APP23 mice passively immunized with Ab
antibodies with titers of 1:4,000 to 1:20,000 (Pfeifer et al., 2002).
APP23 and B6 grafts in APP23 hosts develop amyloid 3 months post-grafting
To study the influence of the host upon amyloid deposition in the graft, we then
intracerebrally grafted cortical and hippocampal APP23 tg and B6 wt control tissue into
the cortex and hippocampus, respectively, of 6 month-old APP23 mice (Fig. 3 and
Table 2). Again, grafts integrated well into the surrounding host tissue and appeared
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healthy and viable by morphological analysis with no evidence of neurodegeneration.
Strikingly, after only 3 months post-grafting, tg grafts developed significant amounts of
amyloid (Fig. 3A-C). Even more surprising, amyloid deposition was also found in wt
cortical and hippocampal grafts 3 months post-grafting (Fig. 3D-I and Table 2).
Amyloid deposition occurred throughout the grafts, with the greatest accumulation
along the border of the graft. At this age the host tissue has also developed amyloid
plaques, but in most animals they were significantly fewer than in the grafts.
Semiquantitative analysis of double-stained sections for Ab and Congo red indicated
that 50% and 12% of the amyloid was compact in tg and wt grafts, respectively (Fig. 3I
insert). Immunohistochemical analysis with antibodies specifically to Abx-40 and Abx-
42 revealed the presence of both Ab species in the graft with a predominance of Abx-40
over Abx-42 (Fig. 4A,B). Immunolabeling with an antibody that recognizes mouse but
not human Ab showed very faint labeling of the amyloid deposits suggesting that
minimal amounts of mouse Ab may contribute to the amyloid in wt grafts (Fig. 4C), as
was also seen for the host tissue amyloid. Ab was also immunoprecipitated from
micropunches taken from amyloid-bearing wt grafts. Results revealed again both human
Ab1-40 and Ab1-42 in the graft similar to that seen in aged amyloid-depositing APP23
mice (Fig. 4D,E).
Mechanism of amyloid formation in B6 grafts
To study whether the site of the graft placement may influence Ab formation in the
grafts, we injected hippocampal and cortical wt tissue into either the thalamus or
striatum of 6 month-old APP23 mice (n =4 for thalamus and n =8 for striatum). Grafts
were analyzed 3 months later. Thalamus and striatum were selected because they
markedly differ in amyloid deposition in APP23 mice. The thalamus develops
significant amyloid deposition in aged APP23 mice, while amyloid deposition in the
striatum is low even in aged APP23 mice (Sturchler-Pierrat et al., 1997; Calhoun et al.,
1998). Consistent with the idea that the properties of the surrounding host tissue
influence amyloid deposition in the graft, our results revealed that 2 out of 4 mice
(50%) developed amyloid in the “thalamic” grafts, while 0 out of 8 mice (0%)
developed amyloid in the “striatal” grafts (Fig. 5). To examine whether the influence of
the surrounding host tissue may be explained by differences in soluble extracellular Ab
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levels among the engrafted brain regions, extracellular soluble Abx-40 and Abx-42 was
measured by ELISA in thalamus, striatum, neocortex, and hippocampus of 6 month-old
pre-depositing APP23 mice. Results revealed the highest Ab levels in hippocampus
(Abx-40: 2.61 ng/g wet weight; Abx-42: 0.41 ng/g) and neocortex (Abx-40: 2.42 ng/g;
Abx-42: 0.42 ng/g), followed by the thalamus (Abx-40: 1.94 ng/g; Abx-42: 0.32 ng/g).
The levels in the striatum (Abx-40: 0.71 ng/g; Abx-42: 0.15 ng/g) were more than 50%
lower compared to these other regions. Consistently, recent microdialysis analysis of
Ab also revealed significant lower extracellular soluble Ab concentrations in striatum
compared to hippocampus (Cirrito et al., 2002). Thus, soluble extracellular Ab levels in
the host may determine amyloid deposition in the graft suggesting that Ab is transported
extracellularly from the host into the graft. We also tested the hypothesis that the grafts
in thalamus and striatum differ in levels of Ab-degrading enzymes. However, no
evidence of a difference was found using immunohistochemical analysis of insulin-
degrading enzyme (Qiu et al., 1998) and neprilysin (Iwata et al., 2000) expression in
graft vs. host (results not shown), although expression levels do not necessarily reflect
enzyme activity.
We have also addressed several other hypothetical mechanisms to how Ab may be
transported from the host into the graft. We considered that hAPP/Ab is anterogradely
transported from host tg neurons into the wt graft. It has been described previously that
host axons can penetrate a homotypic transplant, although in very low numbers (Clinton
and Ebner, 1988). Moreover, APP is anterogradely transported to synaptic sites where it
is released (Lazarov et al., 2002). Thus, we have used Holmes silver staining to
visualize processes between host and graft. Overall, fiber density within the graft was
much lower compared to the host. Although a few fibers were found to cross the host-
graft border, most of the fibers were confined to their host or graft compartments (Fig.
6A). Moreover, immunohistochemistry did not reveal any hAPP-positive fibers that
penetrated significantly into wt grafts (Fig. 6B, but see also Fig. 3E,H).
We also considered the possibility that microglia transport APP/Ab from the host into
the graft. Thus, not the graft per se but the lesion-associated gliosis or inflammation
may induce amyloid accumulation in wt grafts. In favor of this explanation is the
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observation that amyloid was predominantly observed at the border of the graft, an area
of a slightly higher density of microglia compared to the rest of the graft. To test this
possibility, we performed stab wounds in the neocortex and hippocampus of 6 month-
old APP23 mice and analyzed the mice 3 months later. However, in none of lesioned
mice (n =4) was amyloid found despite appreciable microgliosis around the lesion site,
which was more extensive compared to that seen at the host-graft border (Fig. 6C,D).
Moreover, we have injected three APP23 mice with wt grafts in which cells were killed
by freezing before transplantation. Again, no amyloid accumulation was found although
microgliosis was clearly present (not shown). Thus, surgical trauma alone is insufficient
to induce b-amyloidosis in APP23 mice.
These results favor the idea that soluble and diffusible Ab is transported extracellularly
via interstitial fluid from the host into the graft where Ab undergoes fibril formation and
deposition. To exclude the hypothesis that host-derived soluble extracellular Ab is
internalized by wt neurons in the graft and that such internalized Ab is the nidus and a
prerequisite for extracellular amyloid plaque formation, we have used
immunohistochemical staining with a variety of antibodies to Ab, including antibodies
previously suggested to recognize intracellular human Ab  (Wirths et al., 2002).
However, no evidence for intracellular human Ab in the wt graft was found (Fig. 6E,F).
Amyloid-associated pathology in B6 grafts
The observation of amyloid in wt grafts allowed us to study the impact of host-derived
extracellular amyloid formation on neurodegeneration. Although most of the amyloid in
wt grafts was of the diffuse type and did not induce any notable neuropil changes, some
compact and congophilic amyloid plaques were observed (Fig. 3I insert, 7A). Only a
few neuronal cells were observed in the area proximal to compact plaques and some of
them showed signs of degeneration (Fig. 7B). Moreover, plaques were surrounded by
dystrophic synaptophysin-positive boutons (Fig. 7C) and abnormal thickened
acetylcholinesterase-positive processes (Fig. 7D). A subpopulation of these distorted
neuritic structures were positive for hyperphosphorylated tau (Fig. 7E). Signs of gliosis
and neuroinflammation were also evident by clusters of darkly stained complement
receptor 3 (CD11b)-positive and ionized calcium binding adaptor molecule 1 (Iba1)-
positive microglia cells with hypertrophic processes that cover the amyloid core (Fig.
7F,G). Hypertrophic reactive glial fibrillary acidic protein (GFAP)-positive astrocytes
58
were also oberved around the amyloid deposits (Fig. 7H). Overall, these changes
appeared similar to the amyloid-associated degeneration, microgliosis and reactive
astrocytosis previously described in amyloid-depositing APP23 mice (Sturchler-Pierrat
et al., 1997; Calhoun et al., 1998; Phinney et al., 1999; Stalder et al., 1999; Boncristiano
et al., 2002; Bondolfi et al., 2002).
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2.4 Discussion
Whether cerebral amyloidosis is initiated by a gradual increase in extracellular Ab or by
the formation of intracellular Ab aggregates with subsequent accumulation in the
extracellular space (ECS) is controversial (Martin et al., 1994; Hartmann et al., 1997;
Geula et al., 1998; Gouras et al., 2000; Kane et al., 2000; Walsh et al., 2000; Bayer et
al., 2001; D'Andrea et al., 2001; Wirths et al., 2001). Our results suggest that local
intracellular Ab is not a prerequisite for extracellular amyloid deposition and that
amyloid deposition is not necessarily confined to the region of Ab production. Rather,
Ab can be transported and/or diffuses considerable distances in ECS of the brain before
it aggregates, deposits extracellularely and causes neurodegeneration.
First, we have grafted APP23 tg tissue into wt hosts. Because cerebral amyloidosis in
the neocortex and hippocampus of APP23 tg mice appears at six months of age
(Sturchler-Pierrat et al., 1997), our initial expectation was that tg neocortical and
hippocampal grafts placed in wt hosts would also develop amyloid at about six months
post-grafting. However, no Ab deposition was observed in the tg grafts up to twenty
months post-grafting despite APP/Ab production in the tg graft similar to APP23 tg
mice. Thus, a reasonable explanation for this lack of or delay in amyloid formation is
that extracellular Ab in the graft does not reach high enough concentrations for amyloid
formation due to movement of extracellular soluble Ab out of the graft into the large
volume of surrounding host tissue. It has previously been shown that extracellular Ab is
transported via interstitial fluid to the vasculature where Ab is cleared by drainage along
the perivascular spaces into the lymph nodes and/or by transport through the blood-
brain-barrier into the blood (Weller, 1998; Calhoun et al., 1999; Shibata et al., 2000;
DeMattos et al., 2002). That Ab is transported from the tg graft into the wt host is
consistent with the observation of amyloid outside the tg graft, in particular in vessel
walls.
Second, the most compelling evidence that Ab is extracellularely transported between
host and graft comes from our observation that wt grafts in tg hosts exhibit amyloidosis.
The amyloid in wt grafts is largely human Ab and thus transgene- and host-derived.
Moreover, amyloid in wt graft only develops when grafts are placed in brain areas such
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as neocortex, hippocampus, and to some extent thalamus, that have relative high levels
of soluble extracellular Ab, but not when placed into the striatum, which has significant
lower concentrations of extracellular soluble Ab. Finally, axonal transport and transport
by microglia of Ab from the host into the graft did not appear to be significant. Thus,
our results argue strongly that soluble Ab from the tg host is transported extracellularly
via the interstitial fluid from the host into the graft where Ab then undergoes deposition.
Recent findings have suggested that synaptic dysfunction may precede frank neuronal
degeneration in AD and that this dysfunction may be caused by extracellular, diffusible
oligomeric assemblies of Ab (Selkoe, 2002). Our results would also suggest that such
soluble Ab aggregates may diffuse over considerable distances in the ECS and therefore
may have an unexpected ability to impact synapses distal to the site of Ab production.
It could be argued that host-derived human Ab may be internalized by neurons within
the wt graft (Bi et al., 2002; Nagele et al., 2002) and that such internalized human Ab
may undergo fibril formation intracellularly prior to being released and providing the
nidus for extracellular amyloid formation (Gouras et al., 2000; Walsh et al., 2000; Bayer
et al., 2001; D'Andrea et al., 2001; Wirths et al., 2001). However, we found no evidence
of intracellular human Ab in wt grafts. Additionally, we did not find evidence that the
amyloid in wt grafts consisted of significant amounts of mouse Ab, which might have
originated in neurons within the wt graft. Moreover, we have previously reported no
difference in amyloid deposition between APP23 mice on a wt background and APP23
mice on a App-null background (Calhoun et al., 1999). Thus, intraneuronal Ab does not
appear to be a prerequisite for extracellular amyloid formation. Nevertheless, a
contributing role of intraneuronal Ab to extracellular amyloid deposition cannot be
entirely ruled out. The relatively lower amount of compact amyloid in the wt grafts vs.
tg grafts (both in tg hosts) may be explained by amyloid formation initiated by an
intracellular nidus leading to predominantly compact amyloid plaques while the
formation of amyloid in the ECS is largely of the diffuse type. However, these
differences may simply be explained by an Ab concentration difference given that the tg
graft produces Ab in addition to that provided by the surrounding host tissue.
The unexpected observation that wt grafts often had amyloid deposition prior to the tg
host tissue, suggests that the graft provides a particularly favorable environment for
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amyloidogenesis. Increased levels of extracellular matrix proteins in the ECS of neural
grafts (Gates et al., 1996; Sykova et al., 1999) may act as chaperones for Ab fibril
formation or promote amyloidogenesis by inhibiting interstitial fluid transport of Ab to
the vessels and subsequent drainage (Snow et al., 1994; Gates et al., 1996; Weller,
1998; Sykova et al., 1999). Using diffusion-weighted MRI, we have recently shown that
amyloidosis in APP23 mice is closely related to a decrease in brain ECS diffusion
properties (Mueggler et al., unpublished data). Interestingly however, the induction of
extracellular matrix constituents by a stab wound or by the injection of dead cells does
not promote amyloid deposition in APP23 tg mice. Thus, in future studies it will be
important to characterize the factors that promote amyloidogenesis in the wt grafts.
Identifying such amyloid-promoting factors may provide additional targets for amyloid-
lowering therapies.
Whether neurodegeneration is related to intracellular Ab generation or to its
extracellular deposition is key to understanding the pathobiology of AD (Selkoe, 2001).
Oligomerization and accumulation of intracellular Ab1-42 in AD has been consistently
reported (Hartmann et al., 1997; Wild-Bode et al., 1997; Gouras et al., 2000; Walsh et
al., 2000; Wirths et al., 2001). Based on these findings, it has been suggested that
accumulation of Ab1-42 in intracellular compartments may lead to neuronal death
(Walsh et al., 2000; D'Andrea et al., 2001; Wirths et al., 2001). However, our findings
of amyloid-associated nerve cell degeneration, with dystrophic neuritic and synaptic
structures including hyperphosphorylated processes in the vicinity of compact amyloid
deposits in wt grafts, suggest that intracellular Ab  is not a prerequisite for
neurodegeneration. In fact, amyloid pathology in wt grafts is very similar to that
previously described in APP tg mice, including neuron death in the vicinity of amyloid
plaques (Calhoun et al., 1998; Bondolfi et al., 2002; Urbanc et al., 2002), synaptic
abnormalities (Phinney et al., 1999), dystrophic cholinergic processes (Wong et al.,
1999; Boncristiano et al., 2002), and tau hyperphosphorylated distorted neuritic
structures (Sturchler-Pierrat et al., 1997). Moreover, the gliosis and the increase in
neuroinflammatory markers was also similar between wt grafts with amyloid and
amyloid-depositing APP tg mice (Sturchler-Pierrat et al., 1997; Frautschy et al., 1998;
Stalder et al., 1999).
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In conclusion, our grafting experiments demonstrate that cerebral b-amyloidosis does
not require locally generated intracellular Ab to initiate Ab deposition. Indeed, transport
or diffusion of Ab in the ECS of the brain is sufficient and can lead to amyloid
pathology at a considerable distance from the site of Ab generation. Overall, our
findings demonstrate that factors beyond those directly involved in cellular Ab
production and intracellular Ab metabolism are important for amyloidogenesis in vivo.
The amyloid-associated pathology in wt grafts further suggests that neurodegeneration
in AD is dependent, at least partially, upon extracellular amyloid accumulation.
2.5 Materials and Methods
Donor embryos for grafting
Donor mice were C57BL/6 (B6) mice (RCC, Füllinsdorf, Switzerland) and APP23 tg
mice (Sturchler-Pierrat et al., 1997). APP23 mice overexpress mutated human APP
(hAPP) with the Swedish double mutation under a neuron-specific murine Thy-1
promoter element. All APP23 mice were from generation 9-11 of backcrossing to B6.
To produce tg grafts, homozygous male APP23 tg mice were bred with hemizygous
female APP23 mice. For wt grafts B6 mice were bred. Pregnant females were staged by
vaginal plugs and embryos at E15-17 (crown to rump length: 13-15 mm) were taken for
grafting.
Intracerebral grafting
Embryonic neocortices and hippocampi were dissected on ice under semi-sterile
conditions in Dulbecco’s modified Eagle’s Medium (Life Technologies, Basel,
Switzerland). All neocortical tissue pieces from the entire litter were pooled. The same
procedure was performed for the hippocampal pieces. Cell suspensions were prepared
mechanically through repeated pipetting with Pasteur pipettes on ice. Total cell counts
and cell viability were determined with a hemocytometer and 0.4% trypan blue stain
(0.4%; Fluka, Buchs, Switzerland). Cell number was adjusted to 100,000 cells/ml and
cell viability was 80%.
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Host mice (3-24 month-old, females) were anaesthetized with a mixture of ketamine
(10mg/kg body weight) and xylazine (20mg/kg body weight) in saline. Bilateral
stereotaxic injections of 2.5ml cortical and hippocampal cell suspensions were placed
with a Hamilton syringe into the neocortex (AP +1.0mm from bregma, L +/-2.0mm, DV
-1.5mm) and hippocampus (AP -2.5mm, L +/-2.0mm, DV -2.5mm), respectively. In
selected mice cell suspensions were injected into the striatum (AP +1.0mm, L +/-
2.0mm, DV -3mm), and thalamus (AP -2.5mm, L +/-1.5.mm, DV -3mm). Injection
speed was 1.25ml/minute and the needle was kept in place for an additional 2 minutes
before it was slowly withdrawn. The surgical area was cleaned with sterile saline and
the incision was sutured. As a control, some mice received stab wound lesions, i.e. the
needle was lowered in the brain without injection of any cell suspension. All
experiments were in compliance with protocols approved by the Animal Care and Use
Committee (Veterinäramt, Basel).
Histology and immunohistochemistry
At various time points after grafting host mice were deeply anaesthetized and either
perfused transcardially with 0.1 M PBS (pH 7.4), followed by 4% paraformaldehyde in
PBS (pH 7.4) or brains were removed and immersion fixed for 2d in 4 %
paraformaldehyde in PBS. Brains were then dehydrated overnight in 30% sucrose. After
freezing, 20-30 mm serial coronal sections were cut through the transplants on a
freezing-sliding microtome and collected in 0.1 M Tris-buffered saline (pH 7.4).
Sections were stained histologically with cresyl-violet and immunohistochemically
according to previously published protocols (Stalder et al., 1999) with the following
antibodies: polyclonal antibody NT12 (NT11) to Ab (courtesy of P. Paganetti)
(Sturchler-Pierrat et al., 1997); mouse monoclonal antibody W0-2 specific to human Ab
(Wirths et al., 2002) (courtesy of K. Beyreuther); mouse monoclonal antibody 6E10
specific to hAPP/Ab (Signet Pathology Systems, Inc., Dedham, MA, USA); monolconal
antibodies specific to Abx-40 (JRF/cAb40/10) and Abx-42 (JRF/cAb42/26) (Mathews
et al., 2002); monoclonal antibody specific to rodent/mouse Ab that does not cross-react
with human Ab (JRF7rAb1-15/2) (Mathews et al., 2002); polyclonal antibody A4CT to
the C-terminal 100 amino acid of hAPP (courtesy of K. Beyreuther); mouse monoclonal
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antibody 56C6 to neprilysin (CD10; Novocastra Laboratories, Newcastle upon Tyne,
U.K); polyclonal affinity-purified antibody IDE-1 to IDE protein (courtesy of D.
Selkoe); polyclonal antibody to synaptophysin (Dako, Glostrup, Denmark), mouse
monoclonal antibody AT8 which recognizes hyperphosphorylated tau (Innogenetics,
Heiden, Germany), rat monoclonal antibody to CD11b (Mac-1; Serotec, Oxford, UK),
polyclonal antibody to Iba1 (Ohsawa et al., 2000) (courtesy Y. Imai) and polyclonal
antibody to GFAP (Dako). Some sections were double stained with NT12 and Congo
Red. Additional sections were stained histochemically for acetylcholinesterase
(Boncristiano et al., 2002) and Holmes silver staining.
Assessment of APP and Ab in graft and host using Western blotting
Under deep inhalation anesthesia, engrafted mice were sacrificed by decapitation.
Brains were removed and sectioned on a vibratome (400mm thick slices) in ice-cold
PBS. Slices were transferred onto a glass slide on ice. With the aid of a dissecting
microscope and a Stoelting micropunch device (Stoelting, Wood Dale, IL, USA),
micropunches were taken from the graft. For comparison, micropunches were also taken
from normal APP23 and B6 mice. Punches had a diameter of 0.74 mm and thus
consisted of 172 mg wet weight tissue (Palkovits, 1983).
To determine hAPP expression, punched samples were diluted in 30 m l of
homogenization buffer (50 mM Tris, pH 8; 150 mM NaCl; 5 mM EDTA; protease
inhibitor cocktail (Roche Diagnostic, Mannheim, Germany) and 90 ml sample buffer
(0.48 M Bistris; 0.21 M Bicine; 1.33% w/v SDS; 20% w/v sucrose; 3.33% v/v 2-
mercaptoethanol; 0.0053% w/v bromophenol blue). Subsequently, samples were
Dounce-homogenized, sonicated, and subjected to 10% Bicine/Tris 8M Urea SDS-
PAGE (Wiltfang et al., 1997). Proteins were transferred onto a PVDF membrane and
hAPP was detected using monoclonal mouse 6E10 antibody. The secondary antibody
was horseradish peroxidase-conjugated goat anti-mouse IgG (Chemicon, Temecula,
CA, USA). Bands were visualized using SuperSignal“ (Pierce, Rockford, Il, USA) and
developed onto Kodak X-OMAT AR film (Rochester, NY, USA).
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To analyze Ab levels, tissues of two micropunches were combined and human Ab was
immunoprecipitated with antibody 6E10 and protein G Sepharose (Sigma, St Louis,
MO, USA). Subsequent SDS-PAGE and blotting was done as described above.
Synthetic Ab1-40 and 1-42 (Bachem, Bubendorf; Switzerland) was used as control.
Different exposures of the films were digitized and band density measurements for
Ab40 were made using NIH Image Version 1.61 (NIH, Bethesda, MD, USA). Only
bands within the linear range of the film were analyzed.
ELISA to measure soluble extracellular Ab in engrafted brain regions
Neocortex, hippocampus, striatum, and thalamus of 6 month-old male pre-depositing
APP23 mice (n =8) were dissected on ice. Tissue of four mice was pooled and
homogenized in 50mM Tris, pH 8, 150mM NaCl, and 5 mM EDTA and protease
inhibitor cocktail (Roche Diagnostic). The homogenate was centrifuged at 107,000g for
1 hr at 40C and human Abx-40 and Abx-42 levels were determined in the supernatant
by previously described sandwich ELISAs (Mathews et al., 2002). In brief, Ab was
captured with carboxy-terminal monoclonal antibodies that recognize exclusively either
Abx-40 (JRF/cAb40/10) or Abx-42 (JRF/cAb42/26) and detected with horseradish
peroxidase-conjugated JRF/Abtot/17, which was raised against the amino-terminal 16
residues of human Ab. All measurements were done in two or more replica wells.
ELISA results reported are the mean of the two pooled tissue samples (ng Ab per g wet
weight), based on standard curves using synthetic Ab1-40 and Ab1-42 peptide
standards (American Peptide Co. Sunnyvale, CA).
Serum titers of Ab antibodies
At various time points post-grafting (30-510 days), retro-orbital blood samples were
collected from selected engrafted mice by using heparin-coated capillary tubes. Samples
were centrifuged and the sera were immediately frozen on dry ice. Antibody titers were
assessed by ELISA. Serial dilutions of sera were made onto microtiter plates coated
with Ab1-40 (50 ng/ml; Bachem). Detection was through alkaline phosphatase-
conjugated rabbit anti-mouse IgG (Calbiochem, San Diego, USA) and 4-nitrophenol
phosphate disodium salt hexahydrate (Fluka). Titers were defined as dilution yielding
50% of the maximal signal.
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2.7 Figure Captions
Figure 1 Neural grafting of APP23 tissue into B6 hosts.  Embryonic APP23
hippocampal tissue was injected into the hippocampus of 3 month-old wt B6
hosts. Mice were analysed at various times post-grafting (see Table 1).
Shown are mice analysed 3 months (A-C), 18 months (D-F), and 21 months
(G-I) post-grafting. Cresyl violet staining was used to identify the grafts
(asterisks in A,D,G). Immunohistochemistry revealed strong hAPP
expression restricted to neurons in the grafts (B,E,H). Nevertheless, Ab-
immunostaining did not reveal any amyloid deposits 3 and 18 months post-
grafting (C,F). At 21 months postgrafting massive amyloid deposition in
both plaques and vessels was found that was to a great extend congophilic
(i, insert). The bulk of the amyloid was confined to the graft, however, some
vessels with amyloid (arrow) and some diffuse amyloid (arrowhead) were
found outside the graft in the host tissue. Similar results were observed
when cortical tg tissue was injected into the cortex of wt mice (not shown).
Bars are 250 µm (A-C) and 400 µm (D-I).
Figure 2 APP and Aß levels in APP23 grafts placed in B6 hosts. (A) Hippocampus of
a 15 month-old wt B6 mouse that received an APP23 tg graft at the age of 3
months. A micropunch (p) was taken from the graft (asterisk) and subjected
to Western blot analysis. The remaining tissue was immersion-fixed and
immunostained for hAPP demonstrating that hAPP expression was
exclusively confined to the graft. Bar is 150 µm. (B) Western blotting of the
micropunch taken from the APP23 hippocampal graft shown in (A) with
hAb/APP-specific antibody 6E10. In addition micropunches from
hippocampus were taken from young 4-6 month-old APP23 mice and
control B6 mice for comparison. Lane 1: Synthetic Ab40/42. Lane 2: punch
from the hippocampal APP23 graft. Lane 3: punch from B6 hippocampus
(CA1 area). Lane 4: punch from APP23 hippocampus (CA1 area). Note that
hAPP expression and Ab levels in the graft (lane 2) were comparable to that
in APP23 hippocampus (lane 4). In both graft and young APP23 mouse
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Ab1-40 was several fold higher than Ab1-42. (C) Similar analysis as in (B)
but for an APP23 cortical graft 20 months post-grafting. For comparison
micropunches from neocortex were taken from a 12 month-old amyloid-
depositing APP23 mouse and a control B6 mouse. Lane 1: Synthetic
Ab40/42. Lane 2: punch from the cortical APP23 graft. Lane 3: punch from
B6 neocortex. Lane 4: punch from APP23 neocortex.
Figure 3 Neural grafting of APP23 and B6 tissue into APP23 hosts. Embryonic
APP23 tg hippocampal tissue was injected into the hippocampus of a 6
month-old APP23 mouse and analyzed three months later (A-C). Cresyl
violet staining reveals the graft (asterisk) in the dentate gyrus (A).
Immunohistochemistry with an antibody to hAPP reveals robust neuronal
expression of hAPP in the graft and host (B). Immunostaining for Ab in
adjacent sections revealed considerable amyloid deposits in the graft (C).
Strikingly, amyloid deposition in the graft was also found when B6 wt
hippocampal tissue was injected into the hippocampus of a 6 month-old
APP23 mouse and analyzed 3 months later (D-F). In this case no hAPP
expression was found in the graft (E). The same was found when embryonic
B6 wt cortical tissue was grafted into the neocortex of a 6 month-old APP23
mouse and analyzed 3 months later (G-I). Although the majority of the
amyloid was of the diffuse type, some amyloid was compact and Congo red-
positive. The insert in (I) shows an adjacent section stained for Congo red
and viewed under cross-polarized light. Note, that in most cases amyloid
deposition in the graft was more intense compared to the only scattered
amyloid plaques in the 9 month-old host tissue (arrows in F and I). Bars are
90 µm  (A-F) and 50 µm (G-I).
Figure 4 Amyloid in B6 grafts. Immunostaining with antibody JRF/cAb40/10
specific to Abx-40 (A) and antibody JRF/cAb42/26 specific to Ab1-42 (B)
of a B6 wt graft placed in neocortex of an APP23 host. Antibodies specific
to rodent (mouse) Ab (JRF7rAb1-15/2) revealed only very faint labeling of
the amyloid (C). Shown are adjacent sections with arrowheads indicating
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the same amyloid deposits. Note that the faint labeling of vessels and
microglia is due to unspecific labeling of the secondary anti-mouse IgG
antibody. (D) A micropunch (p) was taken from a cortical wt graft (asterisk)
and subjected to Western blot analysis. The remaining tissue was
immersion-fixed and immunostained for hAPP demonstrating that hAPP
expression was exclusively confined to the host. (E) Western blotting of the
micropunch taken from the wt cortical graft shown in (A) with human Ab-
specific antibody 6E10. In addition micropunches were taken from the
neocortex of a 12 month-old amyloid-depositing APP23 mouse and a
control B6 mouse. Lane 1: Synthetic Ab40/42. Lane 2: punch from the
cortical wt graft. Lane 3: punch from B6 neocortex. Lane 4: punch from
APP23 neocortex. Note the presence of both Ab1-40 and Ab1-42 in the wt
graft. Bars are 20 µm (C) and 120 µm (D).
Figure 5 Neural grafting of B6 tissue into thalamus and striatum of APP23 hosts.
(A,B) Embryonic B6 hippocampal tissue was injected into the thalamus of a
6 month-old APP23 mouse and analyzed 3 months later. Cresyl violet
staining revealed that the grafts were nicely integrated into the host
thalamus and are viable without any signs of neurodegeneration (asterisk in
A). Immunostaining for Ab in adjacent sections revealed amyloid deposits
in the graft (B). In contrast, when embryonic B6 tissue was placed into the
striatum of a 6 month-old APP23 mouse, no amyloid formation was
observed 3 months later (C,D). Bars are 250 µm.
Figure 6 Mechanism of amyloid formation in B6 grafts. (A) Holmes silver staining of
the graft-host border of a B6 wt graft (asterisk) in a 9 mo-old APP23 tg host.
There is a lower density of fibers in the graft compared to the host. Only
few fibers cross the host-graft border (dotted line) and most fibers were
confined to either the host or the graft. (B) Consistent with the Holmes fiber
staining, immunostaining for hAPP reveals many positive neurons and
processes in the host tissue, but none in the wt graft. (C) Cortical stab
wound in a tg 6 month-old APP23 host shows an appreciable increase in
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CD11b-positive microglia around the lesion site 3 months post-surgery
(arrowheads). (D) However, immunohistochemistry for Ab in an adjacent
section does not indicate any amyloid deposition in the vicinity of the
lesion. (E) Ab immunostaining with antibody NT12 in the neocortex of a 9
month-old APP23 tg host reveals punctate intraneuronal staining. (F) In
contrast, no evidence of intraneuronal Ab was found in neocortical wt grafts
into APP23 hosts. An amyloid plaque in the wt graft is shown by an
arrowhead. The same results were observed with monoclonal antibody W0-
2 specific to human Ab. Bars are 10 µm (A,B), 100 µm (C,D), and 15 µm
(E,F).
Figure 7 Amyloid pathology associated with congophilic amyloid plaques in B6
grafts. (A) Compact plaque in B6 wt graft in a 9 month-old APPP23 tg host
reveals birefringence when viewed under cross-polarized light (double
staining for Ab and Congo red). (B) Cresyl violet staining demonstrates
only a few neuronal cell bodies at the plaque periphery and some of them
with a dying phenotype (arrow). (C) Plaques are surrounded and
interdigitated by synaptophysin-positive dystrophic boutons (arrows). (D)
Acetylcholinesterase-staining reveals abnormal large cholinergic processes
in vicinity of the plaque (arrow). (E) Some of these abnormal and distorted
processes in the plaque periphery were positive for hyperphosphorylated tau
(arrow). (F) CD11b-immunostaining demonstrates hypertrophic microglia
clustered around compact amyloid plaques. (G) Amyloid-associated
microglia were also intensively positive for Iba1 similar to those observed in
amyloid-depositing APP23 mice. (H) GFAP-staining reveals hypertrophic
and reactive astrocytes decorating the plaque periphery.  Bars are 25 µm
(A,B), 10 µm (C), 25 µm (D), 6 µm (E), 25 µm (F), 30 µm (G) and 25 µm
(H).
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Table 1: APP23 embryonic tissue transplanted in B6 brain
Post-grafting interval
Host Agea 3 mo 6 mo 12mo 18 mo > 20
mo
B6 3 mo 0b/12c 0/6 0/6 0/20 2/9
B6 16 mo 0/1 0/2 0/6
B6 24 mo 0/2 0/5
a age of the host at time of transplantation
b number of mice with amyloid deposits in at least one graft
c total mice analyzed
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Table 2:   APP23 and B6 embryonic tissue
                 transplanted in APP23 brain
Graftsb
Host Agea APP23 B6
APP23 6 mo 7c/7d 10/13
a age of the host at time of transplantation
b mice were sacrificed 3 months post-grafting
c number of mice with amyloid in at least one graft
d total mice analyzed
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3.1 Abstract
The misconformation and self-assembly of specific proteins is well established as a
disease process in Alzheimer’s disease (AD), but little is known about how protein
aggregation is initiated in vivo. Seeded polymerization of amyloid beta (Ab) has been
demonstrated in vitro and has recently also been achieved in vivo by intracerebral
injection of AD brain extract into young amyloid precursor protein (APP) transgenic
mice prior to plaque formation. We have confirmed and advanced these findings
through studies involving injection of diluted brain extract from AD patients and from
aged APP23 transgenic mice into young APP23 mice. Similar to the AD extract,
transgenic mouse brain extract induced massive seeded Ab deposits in the brain
parenchyma and vessel walls four months post-infusion. This seeding was time- and
concentration-dependent. These seeded amyloid deposits were mostly diffuse in nature,
with some congophilic plaques and vessels. Surprisingly, intracerebral injection of
synthetic Ab resulted so far in only limited Ab seeding deposition compared to that
obtained with Ab-rich brain extracts. Studies with fresh and aged synthetic
Ab40, Ab42 and a mixture of Ab40/42, with levels matching that in AD brain extracts,
are ongoing. These studies will unequivocally determine whether Ab alone is sufficient
to induce seeding, and more specifically, which conformational state of Ab has intrinsic
properties to act as a seeding agent.
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3.2 Introduction
Misfolding, aggregation and abnormal accumulation of proteins is a common feature of
many neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s
disease and Creutzfeldt-Jacob disease. Genetic studies support the view that Ab fibril
formation is a central process in AD pathogenesis (Hardy et al., 1998) and accompanied
by neurofibrillary tangle formation, neuron and synapse loss, neuroinflammation, and
dementia (Yankner, 1996; Selkoe, 1999; Gotz et al., 2001; Lewis et al., 2001).
However, little is known about how protein aggregation and deposition is initiated in
vivo.
Protein aggregation in vitro is dependent on protein concentration and time (Jarrett and
Lansbury, 1993; Harper and Lansbury, 1997; Lansbury, 1997). The relatively slow
nucleation process of Ab can be accelerated by introducing an exogenous seed which
then leads to rapid Ab aggregation (Koo et al., 1999). Similar to these in vitro findings,
seeded aggregation may also determine the onset and progression of amyloid formation
in amyloid precursor protein (APP) transgenic mice and in AD.
In the past, there have been many attempts to induce AD neuropathology in animal
models by injection of Ab peptides. Microinjection of fibrillar Ab into the cerebral
cortex of aged rhesus monkeys resulted in profound neuronal loss and tau
phosphorylation (Geula et al., 1998). Moreover, amyloid cores, isolated from AD
brains, caused neurodegeneration and neurotoxicity when injected into the cortex and
hippocampus of rats (Frautschy et al., 1991; Frautschy et al., 1992). However, none of
these studies has focused on the mechanism of Ab polymerization in vivo. Only recently
has it been described that inoculation of dilute AD brain extracts leads to amyloid fibril
formation in young Tg2576 mice (Kane et al., 2000; Walker et al., 2002). Nevertheless,
it remains to be clarified which factors initiate and are involved in this seeding process.
To this end, we have injected diluted brain extracts from AD patients and from aged
APP23 transgenic mice into young APP23 mice prior to plaque formation. Our results
indicate that Ab-containing human and transgenic mouse brain extracts can induce
cerebral amyloidosis in APP23 transgenic mice in vivo.
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3.3 Results
Intracerebral injection of brain extract of aged APP23 mice induces amyloid formation
in brains of young APP23 mice similar to that of AD brain extract
To determine whether brain homogenate of aged APP23 mice is as potent in inducing
seeding of Ab as AD brain homogenate, we injected both brain homogenates into the
hippocampus of young, 5-month old APP23 mice. These mice were analyzed 4 months
later and, similar to the AD extract, the APP23 brain extract induced robust seeding of
b-amyloid deposits, mainly in the hippocampus (Fig. 1A,B). As expected, intracerebral
injection of control patient extract induced only few amyloid deposits (Fig. 1C). We
observed no seeded amyloid deposits in APP23 transgenic mice injected with wt brain
homogenate or PBS (Fig. 1D,E). Infusion of amyloid-containing APP23 brain
homogenate into non-transgenic littermates did not produce Ab deposition, indicating
that the observed immunoreactivity present at 4 months post-infusion was not due to the
injected material itself (Fig. 1F).
Seeded amyloid is diffuse and occurs in vessels and plaques
Seeded amyloid exhibits a characteristic distribution pattern along the hippocampal
fissure and the granular cell layer of the dentate gyrus, the dorsal lateral geniculate
nucleus, in the vasculature of the thalamus and in pial vessels (Fig. 2A-D). In some
cases, there was a spread of Ab deposits along the corpus callosum (Fig. 2A, right
hemisphere). The seeded material in the parenchyma was mainly diffuse in nature (Fig.
2 A,C) with some congophilic compact plaques in the hippocampal area (Fig. 2E) and
congo red positive vessels in the thalamus (Fig. 2F). Results revealed that not only
tissue near the injection site was affected, but also brain regions away from the infusion
site.
Seeding of Ab is time- and concentration-dependent
APP23 mouse brain homogenate was injected into 5-month-old APP23 transgenic mice
and analyzed after different time points from 1 to 4 months post-infusion.
Immunhistological analysis with an antibody against Ab revealed no amyloid deposits
after 1 month (Fig. 3A). First signs of diffuse seeded amyloid were detectable 2 months
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post-infusion (Fig. 3B). Clearly, 3 months after the inoculation of the brain homogenate,
the typical seeding pattern was visible (Fig. 3C). The highest number of seeded amyloid
plaques was obtained 4 months post-infusion (Fig. 3D). Stereological analysis also
confirmed that the amount of Ab deposition significantly increases with time (ANOVA,
p<0.0001) (Fig. 3E).
To determine if Ab concentration in the brain homogenate influences the seeding
pattern, we injected different dilutions of the tg brain homogenate (0.5% vs. 10%) and
compared the resulting hippocampal amyloid load. Immunohistochemical stainings and
stereological analysis both revealed that the 10% extract exceeded seeding obtained
with the 0.5% extract by a factor of 2 (Fig. 4A,B,C). Thus, these results clearly
demonstrate that seeding of Ab in APP23 mice is a time- and concentration-dependent
process.
Seeded amyloid contains Ab40 and Ab42
The next set of experiments were designed to determine the nature of the seeded protein
deposition. Ab was immunoprecipitated from micropunches taken from hippocampus,
lateral geniculate nucleus and thalamus out of formalin-fixed prestained tissue (Ikeda et
al., 1998) (Fig. 5A-H). These micropunches did not only originate from different brain
regions, but they also differed in the type of amyloid they contained. It was clearly
visible that the hippocampus showed both, diffuse and compact plaques, in contrast to
the only diffuse band in the lateral geniculate nucleus and the mainly congo red positive
compact vessels in the thalamus (Fig. 5B,E,H). Western blot analysis revealed the
presence of Ab in the micropunches (Fig. 5C,F,I). There was a negligible amount of Ab
1-42 detectable in the thalamus with a strong predominance of Ab1-40 over Ab1-42
compared to the hippocampus.
Seeding is an extracellular process
Next, we investigated the ultrastructure of Ab depositions induced by the infusion of
amyloid-containing brain extract. Seeded Ab deposits were mostly of the diffuse type
but some compact plaques were located along the granular cell layer in the dentate
gyrus (Fig. 6A). Ultrastructural analysis revealed that Ab deposits were limited to the
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extracellular space (ECS) by observation under the electron microscope (Fig. 6B). We
found no evidence for intracellular Ab, supporting the idea that seeded amyloid
aggregates are located extracellularly.
Synthetic Ab injections induce only limited seeding properties
To identify the factors that initiated the seeding process in our model, we were
wondering whether Ab itself may be sufficient to achieve the same degree of seeding
seen with Ab-containing brain extracts. Therefore, we injected synthetic Ab40 and
Ab42 peptides in APP23 transgenic mice and analyzed them 1 day and 4 months post-
infusion. After 1 day up to 1 month, we found no immunhistological evidence of the
dilute tg brain extract itself (Fig. 3A). In contrast, we observed big aggregates of the
injected synthetic Ab40 and Ab42 material, respectively (Fig. 7A,B). After 4 months, a
robust seeding pattern was only present in APP23 mice injected with Ab-containing
brain homogenate (Fig. 1A,B). Synthetic Ab40 and Ab42 injections resulted in only a
limited amount of amyloid deposits and failed to induce the same amount of seeding
seen with the brain homogenates (Fig. 7C-F).
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3.4 Discussion
Accumulation of highly insoluble protein aggregates is a hallmark of AD and other
neurodegenerative diseases and considered to be a critical step in disease pathogenesis
(Lansbury, 1997; Koo et al., 1999; Walker and LeVine, 2000). The present study was
undertaken to characterize the mechanism that leads to amyloid formation in APP
transgenic mice in more detail. First, we have confirmed the previous finding (Kane et
al., 2000) that intracerebral injection of AD brain extract into APP transgenic mice
induces Ab deposition. Thus, the AD brain extract provided an extremely potent
seeding agent, but the factors that initiated amyloid formation in these mice still remains
unknown.
Besides the typical extracellular amyloid deposits and the intracellular neurofibrillary
tangles, the AD brain is characterized by a pronounced inflammation with an astroglial
and microglial response and the presence of inflammatory cytokines (Itagaki et al.,
1989; McGeer et al., 1994; Griffin et al., 1995). Research has shown that inflammation
plays a role in plaque formation and it has also been suggested that infectious agents can
initiate seeding (Yucesan and Sriram, 2001; Lin et al., 2002). To rule out the latter
possibility, we also infused Ab-containing tg brain homogenate. Our results revealed
robust seeding with both, human and tg animal brain homogenate 4 months post-
infusion. The control experiments done in wt control littermates confirmed that it was
not the tg injectate itself that was detected 4 month after injection.
The formation of Ab fibrils in vitro occurs via seeded polymerization (Jarrett and
Lansbury, 1993). Ab aggregation is dependent upon Ab concentration and time and
initiated by the formation of an oligomeric nucleus that is thought to be the rate-
determining step of amyloid deposition (Lansbury, 1997). We have tested this theory of
seeding b-amyloid in vivo and found that seeding occurred after a lag phase of 2
months, which increases over time. In addition, plaque formation in our seeding model
appears in a concentration-dependent manner. Thus, we show for the first time that the
complex processes associated with misfolding and accumulation of b-amyloid protein
that emerge from in vitro studies are relevant for in vivo processes.
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Next, we examined the biological properties of the seeded amyloid plaques. APP23
mice develop amyloid plaques and cerebrovascular amyloid throughout the neocortex,
hippocampus and to a lesser extent in the thalamus with the majority of cerebrovascular
amyloid (Sturchler-Pierrat et al., 1997; Calhoun et al., 1999; Winkler et al., 2001). In
the experimental paradigm used here, we always observed a typical seeding pattern with
affected brain areas identical to those of aged, untreated APP23 transgenic mice. Thus,
not only the hippocampus, but also brain regions further away from the injection site
such as thalamus developed seeded plaque formation. This observation is in line with
our previous finding that diffusion of Ab in the extracellular space is an important
parameter for cerebral amyloidosis (Meyer-Luehmann et al., 2003). Alternatively,
axonal transport has also been proposed as possible explanation for the spread of seeded
Ab pathology in the brain (Walker et al., 2002). Electron microspcopy of the dentate
gyrus revealed Ab deposition located between neuron bodies in the extracellular space,
indicating that amyloid formation was induced extracellularly. It has been postulated
that amyloid deposits in vessels contain Ab40 whereas the longer Ab42 form is the
predominant component of parenchymal plaques (Joachim et al., 1988; Gravina et al.,
1995; Herzig et al., 2003). Western blot analysis confirmed that the seeded material
consisted of both Ab  peptides, the Ab40 and Ab42 depending on the form of
aggregates. Thus, with the injection of Ab-containing brain homogenate we induced
seeding of both Ab species, suggesting that the same initial seeding agent could seed
amyloid deposits in the vessels and in brain parenchyma.
Finding out whether Ab is sufficient to induce seeding or whether this process requires
additional factors, is key to the development of therapeutic strategies against cerebral
amyloidosis. Previous attempts to generate consistent amyloid deposition causing
neurodegeneration via injection studies have produced inconsistent results (Frautschy et
al., 1991; Clemens and Stephenson, 1992; Emre et al., 1992; Frautschy et al., 1992;
Games et al., 1992; Kowall et al., 1992; Rush et al., 1992; Stein-Behrens et al., 1992;
Waite et al., 1992; Sigurdsson et al., 1997). Most of these studies used single injections
of Ab peptides into rodent brains, indicating that the method of Ab preparation itself
like peptide concentration or aggregation state represents a common source of variation.
Our data so far favour the possibility of important cofactors because synthetic Ab40 and
Ab42 injections resulted in fewer seeded amyloid deposits than those after tg or AD
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brain homogenate infusion. We hypothesize that additional plaque enhancing factors are
abundant in the brain homogenates since it has been reported that after
immunodepletion of Ab, similar seeding still occurs (Younkin, 1995). TGF-b, heparan
sulfate proteoglycan, apolipoprotein E and Ab43 have been successfully applied in
combination with Ab40 to promote plaque formation (Snow et al., 1994; Wisniewski et
al., 1994; Frautschy et al., 1996; Stephan et al., 2001). Future studies will help to
identify cofactors in the brain homogenate that are required for the initiation of cerebral
amyloidosis in vivo. In particular, the identification of endogenous chaperone molecules
for Ab seeding and/or conditions to transform synthetic Ab into a seeding agent for
cerebral amyloidosis would give new important insights.
Studies with synthetic Ab at concentrations equivalent to those found in Ab brain
extracts are ongoing. In the long run, these studies will hopefully answer the most
fundamental question whether Ab itself is the seeding factor. Additionally, ongoing
analyzes with fresh and aged samples will reveal what conformational state of Ab is
most effective in inducing seeding. Such results will greatly enhance the understanding
of Ab aggregation and early amyloidogenesis in vivo and will provide new therapeutic
targets in the search for compounds that inhibit Ab aggregation.
3.5 Materials and Methods
Tissue extracts and synthetic Ab
Human tissue for preparation of extracts was derived at autopsy from cortices of 2
patients who had died of confirmed AD and from a neurological normal control. Animal
tissue was derived from neocortices of two APP23 transgenic mice and from a wildtype
nontransgenic littermate (Table 1). The tissue samples were fresh frozen and stored at -
80°C. Pieces of neocortex were homogenized at 10% (w/v) in sterile PBS, vortexed,
sonicated for 5 seconds and centrifuged at 3000x g for 5 minutes. The supernatant was
immediately frozen (-80°C) and sometimes further diluted 1:20 to a final concentration
of 0.5%.
Synthetic Ab40 and Ab42 was prepared by resuspending lyophilized Ab40 and Ab42
(Bachem, Bubendorf, Switzerland) in phosphate-buffered saline (PBS), pH 7,4,
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followed by an incubation period of 5 days at 37°C to allow them to aggregate. Ab was
vortexed, sonicated and injected in the same manner as the brain homogenates. Congo
red staining confirmed the formation of fibrils.
Western blot analysis
To determine Ab levels in the brain homogenates used in this study, samples were
further diluted 1 to 4 in sample buffer (0,48 M Bis-Tris; 0,21 M Bicine; 1,32 % (w/v)
SDS; 20% (w/v) sucrose; 3,33 % (v/v) 2-mercaptoethanol; 0,0053% (w/v) bromophenol
blue). Samples were then subjected to 10% Bicine-Tris 8M Urea SDS-PAGE (Wiltfang
et al., 1997). Synthetic Ab 1-40 and 1-42 (Bachem, Bubendorf, Schweiz) were used as
controls. Proteins were transferred onto a PVDF membrane and probed with
monoclonal antibody 6E10 (dilution 1:500). The secondary antibody was horseradish
peroxidase–conjugated goat anti-mouse IgG (Chemicon,Temecula, California). Bands
were visualized using SuperSignal (Pierce, Rockford, Illinois) and developed onto
Kodak X-OMAT AR film (Rochester, New York).
Stereotaxic surgery
Host mice (5 month-old, males) were anaesthetized with a mixture of ketamine (10
mg/kg body weight) and xylazine (20 mg/kg body weight) in saline. Bilateral
stereotaxic injections of 2.5 ml brain homogenate were placed with a Hamilton syringe
into the neocortex (AP -2.5mm from bregma, L +/-2.0mm, DV -1mm) and
hippocampus (AP -2.5mm, L +/-2.0mm, DV -2.5mm), respectively. In an additional
experiment 10 mice were injected unilaterally into the cortex and hippocampus.
Injection speed was 1.25 ml/minute and the needle was kept in place for an additional 2
minutes before it was slowly withdrawn. The surgical area was cleaned with sterile
saline and the incision was sutured. As a control, some mice received stab wound
lesions (n=5), i.e. the needle was lowered into the brain without injection of any cell
suspension.
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Histology and immunohistochemistry
Brains were removed and immersion-fixed for 24 h in 4% paraformaldehyde in PBS,
then dehydrated overnight in 30% sucrose. After freezing, 25 mm serial coronal sections
were cut through the brains on a freezing-sliding microtome and collected in 0.1 M
Tris-buffered saline (pH 7.4). Sections were stained with cresyl-violet and
immunohistochemically according to previously published protocols (Stalder et al.,
1999) with the following antibodies: polyclonal antibody NT12 to Ab (courtesy of P.
Paganetti, Basel, Switzerland) (Schrader-Fischer and Paganetti, 1996); mouse
monoclonal antibody 6E10 specific to hAPP/Ab (Signet Pathology Systems, Inc.,
Dedham, MA, USA); polyclonal antibodies specific to Abx-40 (FCA3340) and 42
(FCA3542) (Barelli et al., 1997), rat monoclonal antibody to CD11b (Mac-1; Serotec,
Oxford, UK), and mouse monoclonal antibody AT8 which recognizes human and
murine tau phosphorylated at S202 and T205 (Goedert et al., 1995). Additional sections
were stained with congo red and viewed under cross-polarized light.
Ultrastructural analysis
Some mice (n=3) were deeply anaesthetized and perfused transcardially with fresh 0.1
M phosphate buffered 4% paraformaldehyde (PFA) and 0.5% glutaraldehyde. Brains
were postfixed in 4% PFA in 0.1 M phosphate buffer (PB) overnight. The next day they
were sectioned on a vibratome and the 40 µm slices were collected in 0.01 M PBS.
Immunohistochemistry was performed as described in a previous publication (Stalder et
al., 1999) except that they were treated with Triton and DMSO (5, 10 and 20%) instead
of H2O2 to perforate the cells. The polyclonal antibody, NT12, served as primary
antibody against human Ab (Schrader-Fischer and Paganetti, 1996) and the visible
reaction was achieved by means of diaminobenzoidine (DAB). For the background
staining, slices were incubated in 0.5% OsO4 and 6.8% sucrose in PBS. After washing
them with PBS, slices were dehydrated in ethanol and acetone and subsequently
incubated overnight in Durcupan® ACM (Fluka Chemie GmbH, Buchs SG, CH)
according to the instructions of Fluka. Finally, the slices were embedded between a
mould parting compound coated slide and coverslipped before incubation at 60°C for 48
hours. Coverslips were removed by means of a glass-cutter and pieces of brain tissue
were excised with a scalpel and subsequently glued on Durcupan-blocs in order to
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dissect them on the ultramicrotome. Semithin cuts (1 µm) were collected on Superfrost
(gel coated) glass slides and some of them were stained with toluidine blue. Ultrathin
cuts (at about 80 nm) were collected on standard 200 mesh copper grids (Provac AG,
Balzers, FL). Investigation of the ultrastructure in the ultrathin brain samples was done
on a Transmission Electron Microscope (Philips EM 900). The high-tension was set to
50 kV in order to achieve an optimal contrast.
Assessment of Ab in different brain regions using Western blotting
Under deep inhalation anesthesia, mice were sacrificed by decapitation. Hippocampi of
unilateral injected mice (n=4) were dissected and homogenized at 10% (w/v) in sterile
PBS, vortexed and sonicated for 5 seconds. In another group of animals (n=3), brains
were removed and sectioned on a vibratome (400mm thick slices) in ice-cold PBS.
Slices were transferred onto a glass slide on ice. With the aid of a dissecting microscope
and a Stoelting micropunch device (Stoelting, Wood Dale, IL, USA), micropunches
were taken from the hippocampus and thalamus of the injected and uninjected
hemisphere, respectively. For comparison, micropunches were also taken from normal
APP23 and B6 mice. Punches had a diameter of 0.74 mm and 0.96 mm and thus
consisted of 172 mg and 362 mg wet weight tissue (Palkovits, 1983). To analyze Ab
levels, tissues of five micropunches were combined and human Ab  was
immunoprecipitated with antibody 6E10 and protein G Sepharose (Sigma, St Louis,
MO, USA). Subsequent SDS-PAGE and blotting was done as described above.
Synthetic Ab1-40 and Ab1-42 (Bachem, Bubendorf; Switzerland) were used as
controls.
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3.7 Figure Captions
Figure 1 Seeding of Ab by infusion of AD and Tg brain extract into APP23 mice.
Brain extract was intracerebrally injected into the hippocampus of 5 month-
old transgenic APP23 hosts (A-E) and nontransgenic littermates of the same
age (F). Mice were analyzed 4 month post-injection. Ab-immunoreactivity
(A-F) in the hippocampus of APP23 transgenic mice after injection of AD
(A) and tg (B) brain extract (10%) reveals similar amyloid deposits. In
contrast, only few and no amyloid deposits are detected when brain extract
of a control patient (C) and wildtype mouse (D) into APP23 transgenic mice
was injected. Similarly, no amyloid is observed, when PBS was injected (E)
into APP23 transgenic mice. No amyloid is observed, when APP23 brain
extract is injected into a wildtype nontransgenic mouse (F). Scale bar: 350
µm.
Figure 2 Regional distribution of seeded amyloid. (A) Ab-immunostaining 4 months
after bilateral injection of tg brain extract (10%) into APP23 mice with local
distribution of seeded amyloid. Shown at a higher magnification (B-D) are
the affected areas indicated by white arrowheads. Ab  deposits are
predominately located in the dentate gyrus, along the hippocampal fissure
(B), as a band in the dorsal lateral geniculate nucleus (C) and in vessels in
the thalamus (D). Congo red stained amyloid plaques in the hippocampus
(E) and congo red positive vessels in the thalamus (F) are shown. Scale
bars: 90 µm (B), 60 µm (C), 25 µm (D), 40 µm (E) and 100 µm (F).
Figure 3 Time course study of seeding in APP23 mice. Transgenic mice were
analyzed after 1 to 4 months post-infusion. (A) Ab-immunoreactivity is
absent 1 month after injection of APP23 brain extract. (B) In contrast, after
2 months seeded amyloid is clearly detectable, distributed along the
hippocampal fissure, dentate gyrus and around blood vessels. The amount of
Ab deposition further increases after 3 and 4 months of incubation (C and
D). Scale bar: 350 µm. (E) Stereological analysis confirms a significant
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increase in amyloid load with increasing post-injection time (ANOVA,
p<0.0001).
Figure 4 0.5% and 10% APP23 brain extract injections into APP23 mice. (A)
Moderate Ab-immunoreactivity in APP23 transgenic mice injected with
0.5% APP23 brain extract compared to Ab-immunoreactivity after
injections with 10% APP23 brain extract (B). (C) Stereological analysis
reveals that 10% APP23 brain extract injections resulted in a significantly
higher seeded amyloid load than injections with 0.5 % tg brain extract
(ANOVA, p< 0.01). Scale bar: 350 µm.
Figure 5 Aß levels in different seeded brain regions. (A,D,G) Hippocampus, dorsal
lateral geniculate nucleus and thalamus of a 9 month-old APP23 mouse after
injection of tg brain extract. Seeding resulted in mostly diffuse amyloid in
hippocampus and dorsal lateral geniculate nucleus and vascular amyloid in
the thalamus. (B,E,H) Micropunches were taken (asterisks) and subjected to
Western blot analysis. Bar is 150 µm. (C,F,I) Western blotting of
micropunches. (C) Lane 1: Synthetic Ab40/42. Lane 2: punch from injected
hippocampus of an APP23 mouse. Note the strong Ab1-40 and Ab1-42
band. (F) Lane1: Synthetic Ab40/42. Lane 2: punch from the dorsal lateral
geniculate nucleus of an APP23 mouse. (I) Lane 1: Synthetic Ab40/42.
Lane 2: punch from the thalamus of an APP23 mouse. Note the strong Ab1-
40 band and the weak Ab1-42 suggesting that Ab 1-40 is the predominant
peptide in seeded vessels.
Figure 6 Ultrastructure of seeded amyloid fibrils in APP23 transgenic mice. (A)
Semithin section of the boundary of the granular cell layer (GCL) and the
hilus (H) of the dentate gyrus of an APP23 mouse injected with tg brain
extract. Ab-immunoreactivity seems to be limited to the extracellular space.
Amyloid plaques are indicated by asterisks. Counterstaining was achieved
by toluidine blue. (B) Ultrastructural analysis reveals that Ab (indicated by
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arrowheads) is located between neurons (N). A closer look suggests that Ab
deposits are located extracellularly. Scale bars: 10 µm (A) and 1 µm (B).
Figure 7 Synthetic Ab peptide injections at 1 day and 4 month post-infusion. One day
after the injection of synthetic Ab42 (A) and Ab40 (B) peptide a clot of the
injected material in the hippocampus is detectable. (C,D) This clot
disappeared and only minimal amount of amyloid deposits in the
parenchyma and vessels were observed 4 month post-infusion. (E,F)
Immunoreactivity is absent in nontransgenic control mice injected with
synthetic Ab40 and Ab42. Scale bar: 350 µm.
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Table 1: AD and animal brain extracts
Case Age PMDa Sex
AD case #1 85 y 6 f
AD case #2 74 y 7 m
Control #1 95 y 27 f
APP23 #1    26 mo - f
APP23 #2    26 mo - f
WT #1    24 mo - f
a Postmortem delay (hours)
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4.1 Abstract
A prominent hallmark of Alzheimer’s disease (AD) pathology is cerebral amyloidosis.
However, it is not clear how extracellular amyloid-b peptide (Ab) deposition and
amyloid formation compromise brain function and lead to dementia. It has been argued
that extracellular amyloid deposition is neurotoxic and/or that soluble Ab oligomers
impair synaptic function. Amyloid deposits, on the other hand, may affect diffusion
properties of the brain interstitium with implications for the transport of endogenous
signalling molecules during synaptic and/or extrasynaptic transmission. We have used
diffusion weighted magnetic resonance imaging (DWI) to study diffusion properties in
brains of young (6-month-old) and aged (25-month-old) APP23 transgenic mice and
control littermates. Our results demonstrate that fibrillar amyloid deposits and
associated gliosis in brains of aged APP23 transgenic mice are accompanied by a
reduction in the apparent diffusion coefficient (ADC). This decrease was most
pronounced in neocortical areas with a high percentage of congophilic amyloid and was
not significant in the caudate putamen, an area with only modest and diffuse amyloid
deposition. These findings suggest that extracellular deposition of fibrillar amyloid
and/or associated glial proliferation and hypertrophy cause restrictions to interstitial
fluid diffusion. Reduced diffusivity within the interstitial space may impair volume
transmission and therefore contribute to the cognitive impairment in AD.
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4.2 Introduction
Alzheimer’s disease (AD) is a late onset progressive neurodegenerative disorder that is
characterized by aggregation of the amyloid-b peptide (Ab) into senile plaques and
cerebrovascular amyloid deposits (Selkoe, 1999). In the past few years, several
transgenic mouse models of cerebral amyloidosis have been generated through
overexpression of mutated amyloid precursor protein (APP). These mice develop
amyloid plaques predominately in neocortex and hippocampus and share many features
with the amyloid deposits in AD brain (Wong et al., 2002). In both AD patients and
transgenic mice amyloid deposits are surrounded by activated microglia, and reactive
astrocytes (Frautschy et al., 1998; Stalder et al., 1999; Akiyama et al., 2000). Diffusion
and drainage of Ab throughout the brain interstitium (Meyer-Luehmann et al., 2003)
and along perivascular pathways (Calhoun et al., 1999; Weller et al., 2002; Preston et
al., 2003) play an important role in the initiation and spread of cerebral amyloidosis.
Once deposited, cerebral amyloid and accompanied pathophysiology may influence
extracellular space volume and interstitial fluid (ISF) diffusion properties. A reduction
in ISF diffusion impairs synaptic and/or extrasynaptic transmission and compromises
neuronal function (Nicholson and Sykova, 1998).
The purpose of this study was to assess the apparent diffusion coefficient of water
(ADC) in brains of APP23 transgenic mice using diffusion-weighted magnetic
resonance imaging (DWI) followed by immunohistochemical analysis of cerebral
amyloidosis. DWI is sensitive to microscopic incoherent motion of water molecules and
can detect disturbances in ion and water homeostasis by measuring the ADC in the
tissue (Moseley et al., 1990; Kauppinen et al., 1993).
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4.3 Results
Reduced cortical Apparent Diffusion Coefficient in aged APP23 mice
Changes in ADC values in relation to cerebral amyloidosis were studied in young 6-
month-old (pre-depositing) and aged 25-month-old male APP23 mice. We focused on
the neocortex, a brain region that exhibits robust age-related congophilic amyloid
deposition in aged APP23 mice, and on the caudate putamen, a brain region that
develops only few and mostly diffuse amyloid in aged APP23 mice (Sturchler-Pierrat et
al., 1997; Calhoun et al., 1998). Three coronal planes were selected and ROI within the
caudate putamen and neocortex were defined (Fig. 1).
In caudate putamen ADC-values did not differ among the four groups of mice (Fig. 2).
In contrast, ANOVA for the neocortex revealed a significant (age)x(genotype)
interaction (F (3,25) = 7.87, p<0.001). Subsequent Tukey post-hoc analysis revealed
that aged APP23 mice had significantly reduced cortical ADC value compared to both
age-matched wt mice (p=0.004) and young APP23 mice (p=0.017) (Fig. 2).
Visual inspection of pseudo-coloured ADC maps (Fig. 3) confirmed the robust decrease
in ADC values in the neocortex.  However, a closer analysis indicated that this decrease
was mainly confined to the medial and dorso-lateral part of the neocortex that
contributed to this decrease. Subregional analysis of neocortical structures (medial,
dorso-lateral and ventro-lateral part, Fig. 1) revealed substantial ADC reductions in the
medial and dorso-lateral cortex of the aged APP23 mice compared to aged-matched
control mice (p=0.012 and p=0.001, respectively). However, ADC-values were not
reduced in the ventro-lateral cortex of aged APP23 mice (Table 1).
Amyloid burden and associated gliosis in aged APP23
Following ADC measurements mice were sacrificed and brains analysed for amyloid
burden. No amyloid plaques were detected in the 6-month-old male APP23 transgenic
mice and in wt control mice (Fig. 4). In the 25-month-old APP23 mice Ab-
immunostaining revealed prominent amyloidosis throughout the neocortex but only
little amyloid in the caudate putamen (Fig. 4D). Quantitative stereological analysis
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yielded an amyloid load of 12.6±1.2 % and 3.1±0.7 % in the neocortex and caudate
putamen, respectively (Table 2). Combined Congo red and Ab-immunostaining
revealed that the amyloid in the neocortex consisted mainly of compact plaques with
some diffuse amyloid, whereas all the amyloid in the caudate putamen was of the
diffuse type (Table 2, Fig. 4; Fig.5 A, B). Interestingly, there was also considerable
region-specific variability in diffuse amyloid in neocortex with the ventro-lateral cortex
exhibiting more diffuse amyloid compared to the dorso-lateral and medial part of the
neocortex (Fig. 4).
Amyloid-associated activation of astrocytes and microglia has been associated with
congophilic amyloid deposition (Frautschy et al., 1998; Stalder et al., 1999).
Consistently, in the neocortex of aged APP23 mice, abundant hypertrophic GFAP-
immunoreactive astrocytes closely associated with Ab deposits were found (Fig. 5C),
whereas in the caudate putamen only modest activation of astrocytes occurred (Fig.
5D). No such astrocytosis was found in neocortex and caudate putamen of young
APP23 mice and wt control mice (Fig. 5E, F). Similarly, numerous Iba1-immunreactive
activated microglia were observed in the vicinity of compact plaques in neocortex of
aged APP23 mice (Fig. 5G) while no such microgliosis was seen associated with the
diffuse amyloid in the caudate putamen (Fig. 5H). No activated microglial cells were
found in young APP23 mice and wt control mice (Fig. 5I, J).
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4.4 Discussion
Diffusion-weighted MRI in APP23 mice revealed reduced ADC values in substantial
portions of the neocortex of aged 25-month-old transgenic mice when compared to age-
matched control mice and to young 6-month-old APP23 mice. In contrast, there was no
reduction of ADC values in the caudate putamen of aged APP23 mice compared to age-
matched wt control mice or young APP23 mice.
Consistent with previous findings (Sturchler-Pierrat et al., 1997; Calhoun et al., 1998)
aged (25-month-old) APP23 mice revealed robust compact Ab plaques in the neocortex
but only few and diffuse amyloid in the caudate putamen. No amyloid deposition was
detected in 6-month-old APP23 mice and in wt control mice. This observation suggests
that the ADC reduction in the neocortex of the aged APP23 mice is related to the
amyloid deposition in the brain of these mice. However, ADC values were not reduced
in all cortical areas containing amyloid. For example, the ventro-lateral part of the
neocortex did not show a reduction in ADC although this region exhibited a significant
amyloid load. Interestingly, this brain region develops more diffuse amyloid compared
to the medial and dorso-lateral parts of the neocortex. Thus, one may argue that not only
the amount of amyloid deposition but also its nature (compact versus diffuse)
determines diffusivity within cerebral tissue.
ADC values in vivo are thought to be affected by the net movement of compartmental
water, transmembrane molecular exchange and hence an alteration of viscosity in the
intra- and extracellular compartments (Le Bihan, 2003). In addition it has been shown
that an increase in the tortuosity of the diffusion paths in the extracellular space leads to
a decrease of the extracellular ADC (Norris et al., 1994; van der Toorn et al., 1996; Le
Bihan, 2003). Increased tortuosity is a characteristic feature of injured brain tissue
(Nicholson and Sykova, 1998; Sykova, 2001). A higher tortuosity may be caused by
macromolecules produced by activated glial cells that in turn and may form diffusion
barriers and lead to an increased tissue viscosity. In addition, astrogliosis and
microgliosis, characterized by glial hypertrophy and an increase in glial number,
interposed between the cells, can form diffusion barriers (Roitbak and Sykova, 1999).
Recently it has been suggested that increased tortuosity during ischemia, and other
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conditions involving cellular swelling, is caused by the formation of dead-space
microdomains in the extracellular space. Such dead-end pores occluding the gaps
between the cells can be formed by astrocytic expansions occurring during gliosis
(Hrabetova et al., 2003).
In APP23 mice a substantial inflammatory reaction is observed and exemplified by
activated and hypertrophic astrocytes and microglia (Sturchler-Pierrat et al., 1997;
Bornemann et al., 2001). This gliosis occurs in vicinity of congophilic compact but not
diffuse amyloid (Stalder et al., 1999). Therefore, we investigated whether ADC changes
found in the present study might be attributable to the gliosis and not the amyloid
deposition per se. Indeed, prominent astrocytosis and microgliosis was observed in the
neocortex with virtually no gliosis in the caudate-putamen in the aged APP23 mice. An
expected difference in gliosis between the medial and dorso-lateral as compared to
ventro-lateral neocortex was less obvious but might have been masked by a ceiling
effect due to a prominent gliosis throughout all neocortical areas. Thus, the observed
ADC reduction in neocortex of aged APP23 mice might be related to the gliosis
associated with congophilic compact amyloid plaques.
ADC measurements in AD patients revealed a loss of diffusion anisotropy in the white
matter and an increased diffusivity within the hippocampus (Sandson et al., 1999). This
ADC increase has been related to a loss of neurons as it correlates with the brain
atrophy observed in the hippocampus (Sandson et al., 1999). However, other studies
reported similar ADC values in the hippocampus of AD patients copared to controls
(Hanyu et al., 1998; Bozzao et al., 2001). These studies suggest that an increase in water
diffusivity due to neuron loss is compensated for by the gliosis that accompanies
neurodegeneration and the accumulation of senile plaques and tangles. Thus, the present
observation of a significant reduction of diffusion in APP23 mice may be explained by
the only modest neuron loss but prominent gliosis in the neocortex of these mice
(Stalder et al., 1999; Bondolfi et al., 2002).
In summary we have shown that aged 25-month-old APP23 mice exhibit reduced
cortical ADC values. This reduction goes in parallel with the formation of compact
amyloid plaques and might be attributable to the pronounced gliosis associated with the
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amyloid deposits. Alterations of ISF diffusion properties may change synaptic and/or
extrasynaptic (volume) transmission and compromise neuronal function (Zoli et al.,
1999). Thus, reduced ISF diffusion may contribute to the cognitive deficits previously
reported in these mice (Lalonde et al., 2002; Kelly et al., 2003) and to the AD cognitive
impairment that has primarily been attributed to neuron and synaptic loss.
4.5 Materials and Methods
Animals
APP23 mice express human mutated APP751 under the control of the murine Thy-1
promoter and exhibit the age-related deposition of cerebral amyloid (Sturchler-Pierrat et
al., 1997). Mice have been generated on a B6D2 background and have subsequently
been backcrossed for more than 8 generations to B6. For the present experiments 6-
month-old (n=8) and 25-month-old (n=10) male APP23 mice and age-matched wild-
type (wt) control mice were used (n=5 and n=6, respectively).
Animal preparation
All animal experiments were carried out in strict adherence to the Swiss Law for
Animal Protection. For MRI experiments animals were anesthetized using an initial
dose of 3 % isoflurane (Abbott, Cham, Switzerland) in air:02 (2:1), intubated with a tube
made from polyethylene (PE; ID/OD: 0.4/0.8 mm) and artificially ventilated using a
ventilator for small animals (KTR 3, Alfos Electronics, Biel-Benken, Switzerland). The
animals were positioned in a cradle made from Plexiglas and kept anesthetized with 1.4
% isoflurane in air:O2 (2:1). The animals were paralysed with 10 mg/kg (intravenously,
i.v.) gallamine triethiodie (Aldrich, Milwaukee, USA) in saline (3 mg/ml). Blood
carbon dioxide levels were monitored transcutaneously (PtcCO2) during the experiment
using a paediatric monitoring device (TCM3, Radiometer Copenhagen) as described in
previous studies (Mueggler et al., 2001). Body temperature was maintained at 36.5 ±1ºC
using warm air, regulated by a rectal temperature probe (MLT415, ADInstruments,
Hastings, UK).
119
MRI protocol
DWI experiments were carried out on a Biospec system equipped with a PharmaScan
70/16 magnet (Bruker Medical System, Ettlingen, Germany) equipped with actively
shielded gradient coils (maximum gradient strength: 200 mT/m; rise time <150 µs). The
radiofrequency probe was a birdcage resonator of 28 mm inner diameter. A spin-echo
sequence with echo time TE=50 ms and repetition time TR=1325 ms comprising a
diffusion-sensitizing pulsed gradient pair according to Stejskal and Tanner (1965) was
used for DWI (Stejskal and Tanner, 1965). Seven 1 mm thick coronal slices, separated
by a 0.6 mm inter-slice gap, were imaged with a field-of-view of 2.56 x 2.56 cm2 and a
matrix size of 128 x 64. For the determination of the apparent diffusion coefficient
(ADC) of water, diffusion-encoding was applied along slice gradient direction (for
coronal images caudal to rostral) with five b-values covering a range from 0 to 2000
s/mm2. ADC values are determined by the volume fraction of the various tissue
compartments and by the water diffusion coefficient within each of these compartments,
which by itself depends on fluid viscosity and tortuosity l, which is a measure for the
steric hindrance of diffusion within a compartment (l2 = free diffusion coefficient/
apparent diffusion coefficient).
Tissue preparation and immunohistochemistry
One day after the DW-MRI experiments mice were sacrificed by decapitation under
deep inhalation anaesthesia. Brains were removed and post fixed for 4d in 4%
paraformaldehyde then dehydrated overnight in 30% sucrose. After freezing, serial
coronal sections of 25 µm thickness were cut on a freezing-sliding microtome
throughout the brains. Sections were stained immunohistochemically according to
previously published protocols (Stalder et al., 1999) by using the avidin-biotin-
peroxidase complex method with SG blue as chromogen (Vector Laboratories,
Burlingame, CA). The following antibodies were used: polyclonal antibody NT12 to Ab
(Sturchler-Pierrat et al., 1997); polyclonal antibody to glial fibrillary acidic protein
(GFAP; Dako, Glostrup, Denmark); and polyclonal antibody to ionized calcium binding
adaptor molecule 1 (Iba1; courtesy of Y. Imai, Tokyo, Japan) (Ohsawa et al., 2000).
Some sections were double stained with NT12/GFAP and NT12/ Iba1 antibodies using
SG blue and DAB as chromogens.
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Stereological assessment of amyloid load
Stereological techniques were used to estimate the amyloid load in the neocortex and
caudate putamen. To this end every 24th section throughout the brain was
immunostained with NT12 yielding 10-12 sections for the neocortex and 4-5 section for
the caudate putamen. The amyloid load was determined by calculating the area fraction
occupied by amyloid in two-dimensional disectors on a single focal plane (20X
objective; 0.45 numerical aperture (Calhoun et al., 1998). One set of sections was
double stained for Congo red and NT12 and the percentage of congophilic (compact)
amyloid was estimated. Stereological analysis was performed with the aid of
Stereologer™ software and a motorized x-y-z stage coupled to a video-microscopy
system (Systems Planning and Analysis, Inc., Alexandria, VA). Region definitions of
neocortex and caudate putamen were based upon mouse brain atlas (Franklin and
Paxinos, 1997).
Data analysis
Quantitative ADC maps were calculated on a pixel-by-pixel basis by linear regression
analysis using the model function:
( )( ) ADCbS/bSln ⋅-=0  [1]
where S(b) refers to the pixel intensity as a function of b  (the diffusion-sensitizing
gradient value), S0 refers to the signal intensity of the pixel with zero diffusion gradient
amplitude (b=0).
Analysis was carried out using in-house developed imaging analysis software (Biomap
v3.1). To assess ADC values from different brain structures regions-of-interest (ROIs)
were defined (Fig. 1).
Statistics
The ADC values of both hemispheres measured in the DWI experiments were averaged
to yield one value per region. Data in text and figures are expressed as mean values ±
standard deviation (SD), unless stated otherwise. Multiple comparisons were evaluated
by the analysis of variance (ANOVA) and subsequent post-hoc group comparison
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(Tukey test). Probability values of less than 0.05 were considered as statistically
significant.
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4.7 Figure Captions
Figure 1 Coronal sections through mouse brain (1.6, 0, -1.6 mm anterior to Bregma)
with regions-of-interest (ROI) selected for quantitative data analysis
indicated. ROI 1 was defined for the lateral and medial caudate putamen.
ROI 2 was defined for neocortex. In a subsequent analysis ROI 2 was
further subdivided into medial (2a) cortex; dorso-lateral cortex (2b), and
ventro-lateral cortex (2c).
Figure 2 Apparent diffusion coefficient (ADC) of water in neocortex (ROI 1) and
caudate putamen (ROI 2) of 6- and 25-month-old APP23 mice and age-
matched littermates (wt). Data reveal a significant reduction of cortical
ADC in aged APP23 animals. Values are given as mean ±SD. *=p<0.05;
**=p<0.01.
Figure 3 Colour-coded representative ADC maps of a coronal brain section at the
level of Bregma for a 6- (A) and 25-month-old APP23 mouse (D) and age-
matched controls (6 months (B), 25 months (C)). ADC values given as 10-6
cm2s-1. A significant ADC decline, colour-coded in blue, is detectable in the
medial and dorso-lateral cortex of aged APP23 mice. In the dorso-lateral
cortex of the 6-month-old APP23 mouse few areas with reduced ADC are
visible.
Figure 4 Histological analysis of Ab deposition in APP23 and wt mice. Ab
immunostaining with the NT12 antibody shows no amyloid deposits in
young wt mice (A), young APP23 transgenic mice (B) and aged wt mice
(C), while aged APP23 transgenic mice displayed massive amyloid deposits
predominantly in neocortex (D).Histological analysis of Ab deposition in
APP23 and wt mice. Ab immunostaining with the NT12 antibody shows no
amyloid deposits in young wt mice (A), young APP23 transgenic mice (B)
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and aged wt mice (C), while aged APP23 transgenic mice displayed massive
amyloid deposits predominantly in neocortex (D).
Figure 5 Activation of plaque-associated astro- and microglia in 25-month-old
APP23 transgenic mice. In aged APP23 neocortex massive compact
amyloid plaque formation was observed (A) whereas in the caudate
putamen only diffuse plaques was found (B). Ab related astrocytosis was
extensive around plaques in the neocortex (C) compared to the weakly
GFAP-positive astroglia in the caudate putamen (D) and in wt control mice
(E,F). Ab deposits in the neocortex of 25-month-old APP23 mice were also
associated with activated and Iba1-immunoreactive microglia (G). In
contrast no activation of microglia was observed in the caudate putamen (H)
and neocortex and caudate putamen of wt control mice (I, J). Bars are
100µm (A,B) and 60µm (C-J).
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5. Conclusion
This thesis aims at understanding some of the underlying mechanisms of plaque
formation and associated neurodegeneration in cerebral amyloidosis. Although the
generation of Ab and the processing of its precursor APP has been studied extensively
at the molecular and cellular level, it still remains a mystery how neuronally derived Ab
propagates and forms fibrillary amyloid deposition in vivo and what factors influence
this pathological process. The availablilty of transgenic mice that reflect the
neuropathological spectrum of AD enabled neuroscientists to explore the relationship
between the pathological features, biochemical abnormalities, and memory dysfunctions
occurring in the human AD brain.
In this thesis, several methods have been applied in order to identify the mechanisms of
cerebral Ab accumulation in vivo. As a first attempt to investigate early stages of
abnormal protein deposition and related neurotoxicity, we have used neural
transplantation techniques. These experiments have shown that neuronally produced Ab
diffuses over considerable distances in the extracellular space of the brain before it
aggregates, deposits extracellularly and finally causes neurodegeneration. There has
been a long debate in the field about the origin of plaques and a longstanding question
in AD research is whether amyloid formation occurs intra- or extracellularly. Our
experiments clearly indicate that cerebral amyloidosis does not require locally generated
intracellular Ab to initiate Ab deposition. We conclude that the properties of the host
influence plaque formation in the transplant and that extracellular amyloid can cause
neurodegeneration in the absence of intracellular Ab production.
The second part of the present study has focused on the identification of factors which
initiate or are involved in the seeding process and that induce Ab fibril formation in
APP23 transgenic mice and in AD patients. Preliminary results indicate that cerebral
amyloidosis can be induced by the infusion of Ab-containing brain extract into APP23
transgenic mice, and that this seeded polymerization of Ab is both time- and
concentration-dependent. Interestingly, the infusion of synthetic Ab peptide has so far
failed to induce amyloid seeding. Future experiments will have to examine whether Ab
itself is the seeding factor, and in particular, what Ab conformation is important to
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initiate plaque formation in vivo. The identification of the seeding agent and cofactors
would open new therapeutic strategies to prevent cerebral Ab deposition in diseases
such as AD.
The findings presented above highlight the importance of transport or diffusion of
soluble Ab in neural tissue as a major factor implicated in amyloid formation and
neurotoxicity. In order to characterize Ab diffusion properties in more detail, non-
invasive diffusion–weighted MRI measurements have been applied to APP23 transgenic
mice in the final part of this thesis. The results strongly suggest that amyloid deposition
and the associated gliosis build a hindrance in the brain tissue leading to decreased
interstitial fluid diffusion properties, which may finally change synaptic and
extrasynaptic transmission. Diffusion measurements by MRI would therefore be a
valuable tool to detect early alterations in the diffusion properties in AD patients.
What can we learn from these studies? The discovery of the underlying origin of
cerebral amyloidosis is important in view of the increasing relevance of protein
misfolding diseases for the aging society. Further progress on the key question about the
mechanism of plaque formation and associated neurodegeneration in cerebral
amyloidosis discussed in this thesis may also shed some light on other protein
misfolding diseases. Uncovering some of the fundamental mechanisms of cerebral
amyloidosis will give us the opportunity to develop new therapeutic strategies in the
future to cure these devastating diseases.
136
6. Abbreviations
Ab b-amyloid
AD Alzheimer’s disease
ADC apparent diffusion coefficient
ALS amyotrophic lateral sklerosis
APP amyloid precursor protein
APOE apolipoprotein E
CBF cerebrovascular blood flow
CSF cerebrospinal fluid
CAA cerebral amyloid angiopathy
DWI diffusion weighted magnetic resonance imaging
ECS extracellular space
FAD familial Alzheimer’s disease
HD Huntington’s disease
IDE insulin degrading enzyme
ISF interstitial fluid
MRI magnetic resonance imaging
NFT neurofibrillary tangle
NSAID non-steroidal anti-inflammatory drugs
PD Parkinson’s disease
PrP prion protein
PS presenilin
SAP serum amyloid P component
TSE transmissible spongiform encephalopathy
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